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eTOC Highlights  
- RPAP1 is a novel RNA Pol II regulator, conserved from plants to mammals 
- RPAP1 depletion erases cell identity gene expression, triggering de-
differentiation 
- Mechanistically, RPAP1 is critical for the Mediator-Pol II interaction 
- RPAP1 preferentially contributes to enhancer-driven gene transcription 
 
 
Blurb 
Lynch et al report a novel regulator of RNA Pol II called RPAP1, displaying 
functional conservation from plants to mammals.  RPAP1 is required to 
establish and maintain cell identity.  Mechanistically, RPAP1 is critical for the 
Mediator-Pol II interaction, thereby preserving normal transcription at enhancer-
driven genes. 
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SUMMARY 1 
The RNA Polymerase II Associated Protein 1 (RPAP1) is conserved across 2 
metazoa and critical for stem cell differentiation in plants, however, very little is 3 
known about its mechanism of action, or its role in mammalian cells.  Here, we 4 
report that RPAP1 is essential for the expression of cell identity genes and for 5 
viability.  Depletion of RPAP1 triggers cell de-differentiation, facilitates 6 
reprogramming towards pluripotency, and impairs differentiation.  7 
Mechanistically, RPAP1 is essential for the interaction between Pol II and 8 
Mediator, as well as for the recruitment of important regulators, such as the 9 
Mediator-specific Pol II factor POLR2M/Gdown1 and the CTD phosphatase 10 
RPAP2.  In agreement, depletion of RPAP1 diminishes the loading of Pol II and 11 
Pol II Ser5 phosphorylation levels and decreases expression of super-12 
enhancer-driven genes.  We conclude that Mediator-RPAP1-Pol II is an ancient 13 
module, conserved from plants to mammals, critical for establishing and 14 
maintaining cell identity. 15 
 16 
Key words: transcription; RNA polymerase II; Mediator; cell identity; 17 
differentiation 18 
19 
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INTRODUCTION 20 
 21 
Coordinated regulation of RNA Polymerase II (Pol II) transcription is central to 22 
cell identity transitions, and reflects a common developmental principle across 23 
the plant-animal divide (Gaillochet and Lohmann, 2015; Levine, 2011; 24 
Meyerowitz, 2002).  High-throughput studies have recently revealed a set of 25 
conserved RNA Pol II-Associated Proteins (RPAP1, 2, 3, 4) sharing multiple 26 
interactions among themselves (Jeronimo et al., 2004, 2007).  RPAP2 is an 27 
atypical phosphatase that targets Ser5P on the Pol II carboxy-terminal domain 28 
(CTD) (Egloff et al., 2012a; Mosley et al., 2009), and RPAP2, RPAP3 and 29 
RPAP4 all have essential roles as nuclear transport chaperones for the Pol II 30 
complex (Boulon et al., 2010; Forget et al., 2010, 2013).  In contrast, the 31 
function of RPAP1 remains uncharacterised in mammals. 32 
RPAP1 is a large (153 kDa) multidomain protein with a high degree of 33 
conservation across species (Jeronimo et al., 2004, 2007; Sanmartín et al., 34 
2011).  Studies in plants, yeasts and mammals indicate that RPAP1 interacts 35 
with the RPB3 and RPB11 subunits of the Pol II complex (Giaever et al., 2002; 36 
Ito et al., 2001; Jeronimo et al., 2004, 2007; Sanmartín et al., 2011).  37 
Importantly, the heterodimer RPB3/RPB11 provides a critical interface of Pol II 38 
with the Mediator complex (Allen and Taatjes, 2015; Davis et al., 2002).  39 
Indeed, a high-throughput screen in yeast indicated that depletion of RPAP1 40 
results in dramatic gene expression changes that were similar to depletion of 41 
the Pol II subunit RPB11, although these changes were not characterized 42 
further (Jeronimo et al., 2004, 2007). 43 
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The multiprotein Mediator complex associates with transcriptional 44 
enhancers through protein-protein interactions, being critical for enhancer-45 
promoter looping (Allen and Taatjes, 2015).  The largest accumulations of 46 
Mediator are in super-enhancers, and super-enhancer target genes are typically 47 
the most important for defining cell identity and the most heavily dependent on 48 
Mediator to drive their transcription by Pol II (Allen and Taatjes, 2015; Hnisz et 49 
al., 2013; Kagey et al., 2010; Whyte et al., 2013) 50 
 RPAP1 was recently identified in plants as a critical factor for 51 
differentiation through promoting developmental gene expression (Muñoz et al., 52 
2017; Sanmartín et al., 2011).  Specifically, in Arabidopsis, RPAP1 was 53 
necessary and rate limiting to initiate stem cell differentiation (Sanmartín et al., 54 
2011, 2012).  Based on this, we hypothesized that mammalian RPAP1 may 55 
also coordinate gene expression and cell identity at a global level.  Here, we 56 
characterize the mammalian homolog of RPAP1 to investigate putative roles in 57 
mammalian transcription and differentiation, and reveal a mechanism involving 58 
direct RNA Pol II regulation by RPAP1 through interaction with Mediator. 59 
 60 
RESULTS 61 
 62 
Mammalian RPAP1 expression  63 
The plant homolog of RPAP1 is highly expressed in stem cells compared to 64 
differentiated cells (Sanmartín et al., 2011). Based on this, we began by 65 
examining RPAP1 expression in pluripotent and differentiated mouse cells. 66 
Compared to adult tissues or mouse embryonic fibroblasts (MEFs), RPAP1 67 
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protein levels were high in embryonic stem (ES) cells, induced pluripotent stem 68 
(iPS) cells, embryo carcinoma (P19EC) cells, and embryoid bodies (EBs) 69 
(Figures 1A, 1B).  Moreover, RPAP1 expression levels decreased during in 70 
vitro differentiation of ES cells by LIF removal and retinoic acid addition (Figure 71 
1C; Figure S1A).  In the case of plants, RPAP1 in stem cells is cytoplasmic and 72 
only enters into the nucleus upon differentiation, suggesting that RPAP1 73 
functions as a differentiation switch (Sanmartín et al., 2011).  Interestingly, we 74 
observed a similar behaviour in mouse cells.  In particular, RPAP1 was mostly 75 
cytoplasmic at the very earliest stages of development in the morula and 76 
blastocyst (Figure 1D), as well as in ES cells undergoing self-renewal (Figure 77 
1E and 1F).  However, RPAP1 became partly nuclear upon ES cell 78 
differentiation (Figure 1E), and completely nuclear in differentiated cells and 79 
tissues (Figure 1G and 1H; S1B).  Indeed, we could detect enrichment of 80 
RPAP1 at gene promoters soon after launching differentiation (Figure 1I).  81 
Moreover, treatment of ES cells with the nuclear export inhibitor leptomycin B 82 
produced rapid nuclear accumulation of RPAP1 (Figure 1F), which, similar to 83 
plants, is consistent with active nuclear export of RPAP1 during stem cell self-84 
renewal.  Therefore, mammalian RPAP1 shares similar expression and 85 
subcellular localization dynamics as observed in plants during the switch 86 
between self-renewal and differentiation. 87 
 88 
Dependence of ES or differentiated cells on RPAP1 expression 89 
To assess the relevance of RPAP1 in cells, we first identified shRNAs that 90 
efficiently downregulated RPAP1 (Figure 1G; S1C; see also below).  RPAP1 91 
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knockdown in non-pluripotent cells, such as human 293T, monkey COS7, 92 
various human cancer cell lines, murine MEFs and immortalized primary 93 
hepatocytes, severely attenuated proliferation, induced senescence, and 94 
triggered apoptosis typically with a delay of 2-6 days (Figures 1J, 1K; and 95 
Figures S1D-G). These observations were recapitulated using a total of three 96 
different shRNAs against RPAP1 (Figure S1F).  Interestingly, while 95% 97 
knockdown of RPAP1 expression had no effect on ES cell viability during self-98 
renewal (Figures 1J, 1K; Figures S1C, S1D and S1H), we were unable to 99 
obtain viable ES clones with complete RPAP1-knockout.  It is important to note 100 
that we successfully targeted RPAP1 using multiple independent CRISPR 101 
delivery systems (transient, constitutive, or inducible), guide RNAs, and several 102 
wild-type or haploid ES cell lines.  In particular, we obtained many ES clones 103 
where RPAP1 suffered small deletions but never a complete loss.  Also, when 104 
using an ES cell line with a LacZ reporter knocked-in within intron 8 of the 105 
RPAP1 gene, we were able to efficiently eliminate LacZ expression using guide 106 
RNAs against the first 7 exons of RPAP1, however, we never obtained clones 107 
with elimination of the remaining wild-type RPAP1 allele (Figure S1I to S1L; 108 
see Methods). Taken together, the data suggest that RPAP1 performs an 109 
essential function in all the cell types tested, including ES cells. 110 
 111 
Inhibition of RPAP1 affects ES cell differentiation 112 
While depletion of ~95% RPAP1 did not affect pluripotent cells under self-113 
renewal conditions (see above), we next assessed differentiation by LIF 114 
removal for 24 or 72 hours (Savatier et al., 1996).  We observed that RPAP1-115 
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depleted ES cells presented a delayed differentiation based on the expression 116 
of pluripotency markers and morphological changes, followed by an increase in 117 
apoptosis (Figure S2A and S2B).  Differentiation of ES cells to embryoid 118 
bodies (EBs) by hanging-drop culture constitutes a longer term and more 119 
complex in vitro differentiation assay.  RPAP1 depletion in ES cells followed by 120 
EB differentiation resulted in severely reduced efficiency of cardiac center 121 
development (formation of beating cell clusters) in EBs (Figure 2A).  In 122 
agreement, analyses of RNA expression also revealed a delay in the loss of 123 
pluripotency markers and delayed induction of cardiac muscle differentiation 124 
markers associated with RPAP1-depleted EBs. (Figures 2B and S2C), 125 
suggesting that a decrease in RPAP1 expression is incompatible with 126 
development.  Impaired cardiac center formation by RPAP1-depleted ES cells 127 
may reflect their impaired capacity to differentiate and/or the accumulation of 128 
dying or dysfunctional cells.  Consistent with a developmental defect, 129 
RPAP1(+/-) ES cells, displayed weak contribution to chimeric off-spring (10 130 
from 254 micro-injected embryos) (Figure S2D). Furthermore, in chimera 131 
crosses to look for germline transmission, we did not obtain mice which were 132 
RPAP1(+/-) or RPAP1(-/-) (0 out of 156 pups born) (Figure S2D). 133 
 To characterize the influence of RPAP1 on early events during the 134 
pluripotency-to-differentiation transition, we performed RNA-seq analyses in ES 135 
cells, control and RPAP1-depleted, after 24 hours of differentiation (LIF 136 
removal).  Of 12,827 transcripts detected, 899 (7.1%) were significantly 137 
differentially expressed in RPAP1-depleted cells (Figure S2E; Table S1). 138 
Global investigation via geneset enrichment (GSEA) and supervised network 139 
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analyses indicated that following RPAP1 depletion, differentiating ES cells 140 
maintained proliferation pathways (Myc and E2F-regulated genesets were 141 
significantly higher) and had an attenuated induction of mesenchymal identity 142 
(epithelial-mesenchymal transition (EMT)-related genesets were lower) 143 
compared to the controls, including key mesenchymal genes, such as Ctgf, 144 
Mest and Col4a2 (Figures S2F to S2I; Tables S1 and S2).  This is consistent 145 
with the delayed loss of pluripotency markers and morphological changes 146 
observed upon differentiation of RPAP1 depleted ES cells (Figures 2A, 2B and 147 
S2C).  Thus, RPAP1 depletion delayed ES cell differentiation, suggesting that 148 
high levels of RPAP1 endow ES cells with the ability to rapidly differentiate, 149 
whereas reduced levels of RPAP1 dramatically slow differentiation.  150 
 151 
Inhibition of RPAP1 induces loss of differentiated identity in MEFs 152 
Since RPAP1 depletion impaired ES cell differentiation, we investigated the role 153 
of RPAP1 in differentiated cells.  Following RPAP1 depletion in MEFs, cells 154 
proliferated and still appeared morphologically normal during days 1-3, prior to 155 
the defects which subsequently emerged at days 4-6 (see above Figures 1I 156 
and 1J; S1D).  Thus, RNA-seq was performed at day 3 in control or RPAP1-157 
depleted MEFs to assess the transcriptome while avoiding death-related 158 
secondary effects.  Nevertheless, transcriptomic alterations were dramatic, with 159 
>52% of the 12,249 genes detected displaying significantly altered expression 160 
(FDR q<0.05; Figure 2C; Table S3).  Using multiple approaches to assess 161 
gene expression, including GSEA, gene ontology and supervised network 162 
analysis, we observed that RPAP1 triggered a rapid and pronounced loss of 163 
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multiple developmental processes and robust erasure of fibroblast identity 164 
within 3 days (Figures 2F to 2H; and S2J, S2K; Table S2 and S3), a 165 
sequence which was initiated within 24hrs as confirmed by qRT-PCR for 166 
multiple mesenchymal/ fibroblastic identity markers (Figures 2G and S2L).  167 
Notably, there was a remarkable parallel between the genesets that were 168 
downregulated in MEFs by RPAP1 loss and the genesets that failed to be 169 
upregulated in differentiating RPAP1-depleted ES cells (Figure 2H).  Lastly, a 170 
defining feature of mesenchymal cell identity is a high capacity for cell 171 
migration.  Consistent with the above gene expression profile, RPAP1-depletion 172 
followed by a wound healing scratch assay revealed an attenuation of MEF 173 
migration capacity (Figure 2I).  In summary, after RPAP1 depletion, MEFs 174 
display rapid de-differentiation via loss of mesenchymal-fibroblastic identity.   175 
 176 
RPAP1-knockdown favors de-differentiation and reprogramming  177 
Since RPAP1 is important for maintaining the mesenchymal cell identity of 178 
MEFs, we hypothesized that RPAP1 depletion may recapitulate an early stage 179 
of reprogramming to iPS.  Previous investigators have found that during 180 
reprogramming there is an initial de-differentiation wave followed by a transient 181 
intermediate state, which is resolved by a second wave of transcriptional 182 
changes leading to pluripotency (Polo et al., 2012).  Interestingly, the gene 183 
expression profile induced by RPAP1 depletion was significantly similar to the 184 
intermediate state of reprogramming (Figures 3A, S3A and S3B).  This was 185 
supported by validation with markers of the intermediate state (Polo et al., 186 
2012), including downregulation of Meox1 and Meox2, and upregulation of 187 
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Nup210 (Figure 3B).  This suggested that RPAP1 knockdown phenocopies the 188 
de-differentiation and loss of mesenchymal identity observed in the first wave of 189 
transcriptional changes during iPS reprogramming.  Consistent with this, prior 190 
knockdown of RPAP1 for 2 days in MEFs led to significantly enhanced iPS 191 
reprogramming with the four Yamanaka factors (Oct4, Sox2, Klf4 and cMyc, 192 
abbreviated as OSKM) (Figures 3C and 3D).  Importantly, therefore, the 193 
lethality of RPAP1 depletion in MEFs was rescued by reprogramming to 194 
pluripotent iPS cells, suggesting that RPAP1-depleted MEFs at days 2-3 may 195 
represent de-differentiated cells without a defined identity, which subsequently 196 
collapse unless rescued re-directed by reprogramming into pluripotency. 197 
 To explore the minimal complement of the Yamanaka factors sufficient to 198 
rescue lethality of RPAP1 depletion and/or confer pluripotency, we tested all 199 
possible combinations of Oct4, Sox2, Klf4, cMyc and Nanog (32 combinations; 200 
OSKMN; Figure 3E), in combination with a panel of media supplements 201 
reported to enhance reprogramming (15 media cocktails; Figure S3C).  Four 202 
interesting features emerged: (i) RPAP1 knockdown plus several of the 203 
transcription factor combinations including Klf4 or cMyc were sufficient to 204 
rescue cell survival, in particular, shRPAP1 with Klf4/cMyc together converted 205 
the majority of MEFs to putative intermediates of reprogramming, that is, rapidly 206 
proliferating colony-forming cells which were also positive for markers of the 207 
early stages of the reprogramming process, including alkaline phosphatase and 208 
SSEA1 cell surface expression, but were Sox2-eGFP-negative (Figures 3E to 209 
3G; and Figure S3D); (ii) RPAP1 depletion increased the efficiency of all 210 
successful reprogramming combinations (Figure 3E); (iii) RPAP1 depletion can 211 
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replace Sox2 in combination with OKM or OKMN (Figures 3E to 3G); and (iv) 212 
pharmacological inhibition of TGFb signaling, which is known to replace Sox2 213 
(Li et al., 2010), cooperated with RPAP1 depletion in the OKM or OKMN 214 
reprogramming (Figure S3E).  Taken together, phenotypic and expression data 215 
suggest that RPAP1 depletion induces a de-differentiated state that can be 216 
stabilized by Klf4/cMyc, and can be converted into full pluripotency if Oct4 is 217 
included. 218 
 219 
RPAP1 regulates the Pol II interactome, not its expression or localization 220 
To understand the mechanism by which RPAP1 is required for somatic cell 221 
proliferation, we first wondered if RPAP1 could affect the stability and 222 
localization of Pol II.  The Pol II complex is formed by 12 subunits (RPB1-12, 223 
RPB1 being the largest and catalytic subunit) and 4 associated proteins 224 
(RPAP1-4) (Wild and Cramer, 2012). The full complex is assembled in the 225 
cytoplasm and remarkably individual depletion of the subunits RPB2 to 12 or 226 
RPAP2 to 4 prevents nuclear import of the catalytic subunit RPB1 (Boulon et 227 
al., 2010; Forget et al., 2010, 2013; Wild and Cramer, 2012), whereas the effect 228 
of RPAP1 depletion has not been reported.  Therefore, we assessed the effect 229 
of RPAP1 knockdown on Pol II expression and localization in five different cell 230 
lines.  In contrast to the above-mentioned subunits, RPAP1 depletion did not 231 
affect total Pol II expression levels, its global modification status by 232 
phosphorylation on serine 5 (Ser5P) or serine 2 (Ser2P) (Figure 4A and Figure 233 
S4A and S4B), or its nuclear localization (Figure 4B and S4C).  This was 234 
confirmed by immunofluorescence (Figure 4C and Figure S4D). These 235 
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observations rule out Pol II destabilization and/or mislocalization as an 236 
explanation for the essential role of RPAP1 in the survival of differentiated cells. 237 
We further investigated the mechanism by which RPAP1 might regulate 238 
Pol II.  Since RPAP1 is a large protein directly associated with Pol II (see: 239 
Introduction), we compared the Pol II protein interactome of control vs. RPAP1-240 
knockdown MEFs in order to detect changes in Pol II function through 241 
alterations in its binding partners.  Immunoprecipitation of RPB1, the largest and 242 
core Pol II sub-unit, followed by mass spectrometry, revealed 294 specific 243 
interactor proteins (Figure 4D; see: Methods), with a clear enrichment for 244 
transcription-related factors, including for example all 12 subunits of the Pol II 245 
complex and almost all (28 out of 30) of Mediator subunits, illustrating the depth 246 
and specificity of this interactome analysis (Table S4).  Importantly, RPAP1-247 
knockdown did not affect the integrity of the Pol II complex itself, but it resulted 248 
in a significant reduction of 104 Pol II interactors (red circles in Figure 4D; see 249 
also Table S4), while 5 new interactors were found (green circles).  Amongst 250 
Pol II interactors significantly affected by RPAP1-depletion, the Mediator 251 
Complex was ranked the highest in terms of proportion of affected subunits 252 
(Figure 4E; Table S4) suggesting an important alteration in the functions 253 
controlled by this complex.  Furthermore, we observed that depletion of RPAP1 254 
led to the loss of POLR2M (also known as Gdown1) from Pol II complexes.  255 
Gdown1 is a recently discovered protein that tightly binds approximately half of 256 
Pol II in cells, forming the so-called Pol II(G) complex (Hu et al., 2006; Jishage 257 
et al., 2012).  Importantly, Pol II(G) complexes are known to contain RPAP1 258 
(Jishage et al., 2012).  We note that Gdown1 is recruited by Mediator and 259 
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associates with Pol II on Mediator-regulated target genes (Cheng et al., 2012; 260 
Hu et al., 2006; Jishage et al., 2012; Li and Price, 2012).  Altogether, we 261 
conclude that RPAP1 is a critical ingredient for Mediator-competent Pol II.  262 
 263 
RPAP1 is required for transcription of identity and developmental genes 264 
Since Mediator has a critical role recruiting Pol II to genes controlling cell 265 
identity and development (Allen and Taatjes, 2015; D’Alessio et al., 2009; Hnisz 266 
et al., 2013; Whyte et al., 2013), we next investigated the global effect of 267 
RPAP1-depletion on Pol II binding to chromatin.  For this, we performed ChIP-268 
seq for total Pol II and for Ser5P Pol II, the latter reflecting active Pol II (Egloff et 269 
al., 2012b; Hsin and Manley, 2012).  Knockdown of RPAP1 in MEFs reduced 270 
the abundance of both total and Ser5P Pol II at about 50% of detected genes, 271 
while very few genes (<0.5%) displayed an increase (Figures 5A-D; Table S5).  272 
Interestingly, GSEA and Leading Edge analyses revealed that mesenchymal-273 
regulators and related developmental processes were among the genesets 274 
(GSEA) and genes (Leading Edge) with the most significant loss of Pol II 275 
(Figures 5E, 5F and S5A; Table S2). 276 
 Pol II regulation at individual genes is often more complex than overall 277 
abundance, particularly in relation to two critical steps, namely, Pol II loading at 278 
promoters and transitioning into productive elongation (Chen et al., 2015; Liu et 279 
al., 2015; Rahl et al., 2010).  Hence, we compared Pol II abundance at 280 
promoter versus gene body, by calculating the promoter-to-body ratio (often 281 
described as the “PI index”), as described (Chen et al., 2015; Rahl et al., 2010) 282 
(Figure S5B).  Overall, in those genes with reliable Pol II signal, we observed 283 
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that 84% of the genes in MEFs had a promoter/body ratio > 2.0 (Figures S5C 284 
and S5D; Table S5), which is similar to published data in mouse ES cells 285 
(91%)(Rahl et al., 2010) or human cancer cells (90%) (Chen et al., 2015).  286 
Following RPAP1 depletion, the promoter/body ratio was altered in many 287 
genes, in some cases it was increased and in others it was decreased (Figure 288 
S5E). Interestingly, while no significant genesets were enriched among those 289 
genes with decreased promoter/body ratios, genesets corresponding to 290 
regulators of cell identity and development were significantly present among the 291 
genes with increased ratios (Figure S5E; Table S5). 292 
To investigate if RPAP1 depletion altered Pol II activity and abundance 293 
through altered Ser5P levels, we calculated the Ser5P/total Pol II ratio (also 294 
known as “Ser5P density”) for all genes at the promoters and gene bodies.  We 295 
detected widespread changes in Ser5P density (Figure S5F), a phenomenon 296 
that has been observed before when Pol II elongation is blocked (Allepuz-297 
Fuster et al., 2014).  Notably, these changes were more pronounced at 298 
promoter regions than at gene bodies (Figure S5F).  Moreover, GSEA analyses 299 
revealed that upon RPAP1 depletion, the only significantly enriched genesets 300 
were associated with increased Ser5P density at promoters, and these included 301 
genesets and GO terms such as TNFa signaling via NFkB, cell migration, 302 
locomotory behavior, and genes in which RNA levels are also downregulated 303 
(Tables S2 and S5), such as Snai2, Tgfb1i1, Tgfb3, Tgfbrap, Lox, Loxl1, Tlr2, 304 
Tlr3, Vegfa, Myo6, Smad6, Ccl7, S100a4 (Fibroblast-Specific Protein1) and 305 
S100a6 (Figure S5F; Table S5).  Taken together, this suggests that RPAP1 306 
depletion affects Pol II transcription, including the levels of Ser5P, and this 307 
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preferentially perturbs the expression of cell identity and developmental 308 
regulators. 309 
In summary, upon RPAP1-knockdown in MEFs, the genes and genesets 310 
linked to the regulation of fibroblastic/mesenchymal identity or closely related 311 
developmental processes were the most significantly enriched in four key 312 
categories: (i) genes with the most significantly downregulated mRNA 313 
expression; (ii) genes with the greatest overall depletion of Pol II; (iii) genes with 314 
selective Pol II depletion from their gene body; (iv) genes with the most 315 
enhanced Ser5P density at their promoters. 316 
 317 
Conservation of RPAP1 function from plants to mammals 318 
Previously, it was shown that mutations of the RPAP1 homolog in plants 319 
inhibited cell differentiation, and microarray analyses showed a specific defect 320 
on developmental gene expression (Sanmartín et al., 2011).  In order to directly 321 
compare the mouse and plant functional overlap, we converted the published 322 
plant differential gene expression data to the nearest mammalian protein 323 
homolog where possible (see Methods and Table S2).  Interestingly, 324 
conversion of the plant expression data to mouse homologs also revealed 325 
significant downregulation of developmental processes (Figure 5F; Table S2).  326 
This suggests that loss of RPAP1 function in mice and plants downregulates 327 
similar developmental processes, including lineage specifiers and regulators of 328 
cell identity, such as hypoxia, cell polarity, extra-cellular matrix, and chemokine 329 
signaling. 330 
 331 
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RPAP1 preferentially regulates Mediator-driven gene expression 332 
Mediator physically links enhancers with target genes, and then recruits Pol II 333 
for their transcriptional activation (Allen and Taatjes, 2015).  This process is 334 
especially critical to maintain transcription of genes regulated by super-335 
enhancers, which typically encode key markers and regulators of cell identity 336 
(Allen and Taatjes, 2015; Hnisz et al., 2013; Whyte et al., 2013).  Given our 337 
observations above that RPAP1-depletion triggered both a decrease in Pol II 338 
interaction with the Mediator complex, and selective loss of cell identity gene 339 
expression, we next assessed the transcription of super-enhancer-driven 340 
genes.  We found that following RPAP1-depletion in MEFs, the mRNA levels of 341 
genes proximal to super-enhancers were significantly decreased (Figure 5G), 342 
whereas, highly expressed housekeeper genes were not affected (Figure S5G).  343 
Expression levels of enhancer RNAs (eRNAs) are proportional to their enhancer 344 
activity (Andersson et al., 2014; Li et al., 2016).  In our RNA-seq, we detected 345 
eRNA expression in ~20% of super-enhancers, and we divided those 346 
enhancers into two groups, those with increased or decreased eRNA levels 347 
(Figure 5H).  Interestingly, after RPAP1-depeletion, enhancers with decreased 348 
eRNA levels (decreased activity) had target genes associated with Theiler 349 
Stages 20-25 (embryo day E11.5-17), while enhancers with increased eRNA 350 
levels (increased activity) had target genes associated with Theiler Stages 14-351 
20 (E8-13) (Figures 5I and S5H).  Since MEFs arise from E13.5 embryos, the 352 
data suggests that enhancers of this embryo stage are decreased in activity, 353 
while enhancers of earlier embryo stages are activated.  This is consistent with 354 
the de-differentiation effects that we observed above in MEFs after RPAP1-355 
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depletion.  Taken together, this suggests that RPAP1 depletion affects Pol II 356 
transcription by disruption of the Mediator-Pol II interaction, and this 357 
preferentially reduces the expression of super-enhancer-driven cell identity and 358 
developmental regulators (Figures 5J and 5K). 359 
 360 
 361 
DISCUSSION 362 
 363 
We have characterized the function of mammalian RPAP1, and observed 364 
prominent parallels with its plant homolog, in terms of sub-cellular localization, 365 
developmental expression patterns, regulation of RNA Polymerase II 366 
transcription, and a requirement to establish and maintain differentiated cell 367 
identity.  Based on this, we propose that this is an ancient mechanism to trigger 368 
the transition from pluripotency to differentiation. 369 
 370 
RPAP1 expression and nucleo-cytoplasmic shuttling 371 
We found that RPAP1 protein is largely cytoplasmic in pluripotent cells, which is 372 
consistent with the lack of effect of RPAP1 depletion on gene expression or 373 
proliferation, in self-renewing pluripotent cells.  However, we were unable to 374 
isolate RPAP1-KO ES cells, suggesting that either ES cells require a small 375 
amount of RPAP1 for an essential function, or to maintain fast proliferation, 376 
under self-renewal conditions.  Interestingly, we observed rapid nuclear 377 
accumulation of RPAP1 by blocking nuclear export, implying a continuous cycle 378 
of RPAP1 in/out of pluripotent cell nuclei.  In contrast, the onset of 379 
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differentiation coincided with RPAP1 nuclear accumulation, observed both in 380 
vitro and in vivo, and recruitment to promoters together with Pol II.  In fact, this 381 
developmental switch in nucleo-cytoplasmic shuttling is similar to the behaviour 382 
of the RPAP1 plant homolog (Muñoz et al., 2017; Sanmartín et al., 2011, 2012).  383 
This is also consistent with the existence of multiple conserved NLS/NES 384 
sequences on RPAP1 and a high homology ARM superfamily repeat region, a 385 
motif associated with nucleo-cytoplasmic shuttling, that is highly conserved in 386 
RPAP1 homologs of Saccharomyces, Drosophila and mammals (Jeronimo et 387 
al., 2004).  Together, this suggests a conserved model for RPAP1 function in 388 
the mechanism for triggering development (Figure 5J).  389 
 390 
RPAP1 is required to establish and maintain cell identity 391 
During development, new cell identity can arise through a series of reversible 392 
epithelial-to-mesenchymal transitions (EMT) (Thiery et al., 2009).  RPAP1 393 
expression was required during ES cell differentiation, including towards cardiac 394 
muscle development, a path containing several EMT transitions(Thiery et al., 395 
2009).  Consistent with this, we failed to obtain homozygous RPAP1-null mice.  396 
Moreover, RPAP1 depletion resulted in a striking loss of the mesenchymal 397 
identity of MEFs and subsequent cell death.  Similarly, all tested cell lines (a 398 
total of 8) died several days after RPAP1 depletion.  Taken together, these data 399 
suggest a role for RPAP1 in both the establishment and maintenance of cell 400 
identity. 401 
 402 
RPAP1 depletion permits de-differentiation and reprogramming 403 
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RPAP1 depletion induced a loss of MEF mesenchymal/fibroblastic identity.  404 
Strikingly however, such de-differentiation complemented the early stages of 405 
reprogramming to pluripotent iPS cells, and thus, RPAP1 depletion enhanced 406 
the efficiency of recapturing pluripotency.  Therefore, reprogramming with 407 
OSKM rescued the lethality of RPAP1 depletion, a phenomenon we found could 408 
be attributed to the overexpression of Klf4 plus cMyc in particular.  We 409 
hypothesize that Klf4/cMyc dual overexpression may revert or compensate the 410 
lethal effects of RPAP1 depletion since cMYC amplifies active Pol II 411 
transcription (Lin et al., 2012; van Riggelen et al., 2010), while the ectodermal 412 
lineage specifier KLF4 may help to specify a new epithelial identity.  In this way, 413 
RPAP1 depletion plus Klf4/cMyc overexpression may stabilize a highly 414 
proliferative reprogramming intermediate. 415 
 416 
RPAP1 acts at the interface between RNA Pol II and Mediator 417 
RPAP1 is a large (153 kDa) multidomain protein that has been reported to bind 418 
a number of interesting Pol II regulators, most notably the RPB3/11 heterodimer 419 
and this is well substantiated in plants, yeasts and mammals (Giaever et al., 420 
2002; Hazbun et al., 2003; Ito et al., 2001; Jeronimo et al., 2004, 2007; 421 
Sanmartín et al., 2011).  Indeed, loss of RPAP1 in yeast produces global 422 
changes in gene expression that resemble those produced by loss of RPB11 423 
(Jeronimo et al., 2004).  The RPB3/RPB11 heterodimer provides the interface 424 
between Pol II and the Mediator complex (Davis et al., 2002).  Importantly, 425 
Mediator plays a critical role in establishing cell identity (Allen and Taatjes, 426 
2015; Hnisz et al., 2013; Whyte et al., 2013), and RPB3 is reported to specify 427 
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muscle identity (Corbi et al., 2002).  Here, we detected a major disruption of the 428 
Pol II interactome following RPAP1-depeletion, and most notably, out of 3,000 429 
known protein complexes in the Corum database, the complex most heavily 430 
affected was the Mediator complex.  Therefore, our current findings suggest a 431 
model whereby RPAP1 operates at the interface between Pol II and Mediator to 432 
direct the transcription of cell identity genes. 433 
 434 
RPAP1 is required for Pol II transcription at cell identity genes 435 
Consistent with the pivotal role of RPAP1 in the Mediator/Pol II axis, we 436 
observed widespread transcriptional changes in RPAP1-depleted MEFs, with 437 
significantly altered gene expression in 52% of all detectable mRNAs, and 438 
decreased Pol II loading in 50-60% of all genes.  However, we also observed 439 
that about 40% of genes displayed minimal changes in Pol II abundance 440 
(Figure 5C), and many highly-expressed mRNAs remained unaffected (Figures 441 
2C and S5G), arguing against a non-specific defect in Pol II transcription.  442 
Furthermore, upon RPAP1-knockdown in MEFs, genes regulating 443 
developmental processes and fibroblastic/mesenchymal identity were the most 444 
significantly affected according to four criteria: (i) downregulated mRNA 445 
expression; (ii) greatest overall depletion of Pol II; (iii) increased Ser5P Pol II 446 
density at promoters; and, (iv) depletion of Pol II within gene bodies relative to 447 
promoters.  These features are consistent with RPAP1 deletion affecting Pol II 448 
loading on promoters and promoter escape into gene bodies.  Remarkably, 449 
these aspects mirror Mediator´s best known functions (Allen and Taatjes, 2015). 450 
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Our proteomic data provide mechanistic explanations for the relative 451 
increase in Ser5P Pol II at promoters and for the relative reduction of Pol II from 452 
gene bodies.  In particular, RPAP1 has conserved interactions with the Ser5P 453 
phosphatase RPAP2 in plants and mammals (Egloff et al., 2012a; Jeronimo et 454 
al., 2007; Mosley et al., 2009; Muñoz et al., 2017).  We observed that RPAP2 455 
phosphatase was depleted from the Pol II interactome upon knock-down of 456 
RPAP1 and this may explain the relative accumulation of Ser5P Pol II at 457 
promoters.  Meanwhile, POLR2M (also known as Gdown1) is a recently 458 
discovered protein, often referred as “the 13th subunit”, that tightly binds 459 
approximately half of Pol II complexes in cells, forming Pol II(G) (Hu et al., 460 
2006; Jishage et al., 2012).  Specifically, Gdown1 is recruited by Mediator and 461 
associates with Pol II on Mediator-regulated target genes (Cheng et al., 2012; 462 
Hu et al., 2006; Jishage et al., 2012; Li and Price, 2012).  It has been reported 463 
that Pol II(G) contains RPAP1 (Jishage et al., 2012), and, here, we show that 464 
depletion of RPAP1 leads to the loss of Gdown1 from Pol II complexes.  465 
Therefore, RPAP1 behaves as a critical ingredient for Mediator-competent Pol 466 
II. 467 
Mediator is most abundant in super-enhancers, and super-enhancer 468 
target genes are typically the most important for defining cell identity and the 469 
most heavily dependent on Mediator to drive their transcription by Pol II (Allen 470 
and Taatjes, 2015; Hnisz et al., 2013; Whyte et al., 2013).  In agreement, the 471 
gene expression of super-enhancer target genes was preferentially decreased 472 
following RPAP1-depletion in MEFs, and this pattern of gene expression 473 
correlates closely with the first 3 days of iPS reprogramming, constituting a de-474 
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differentiation effect.  Consistent with a de-differentiation effect, we observed 475 
that the activity of enhancers, measured by their eRNA levels, shifted from the 476 
developmental stage of MEFs towards an earlier developmental stage.  This is 477 
consistent with recent evidence that during cell identity transitions, coordinated 478 
changes in enhancer activity lead the re-organization of transcriptional networks 479 
(Arner et al., 2015; Factor et al., 2014).  Taken together, the data point toward a 480 
primary role for RPAP1 in maintaining the expression of identity regulators, 481 
through the Mediator/Pol II axis. 482 
 483 
Concluding remarks 484 
Collectively, our data points toward a developmental requirement for 485 
mammalian RPAP1, both in establishing and maintaining cell identity, through 486 
direct regulation of RNA Polymerase II transcription.  Mechanistically, we 487 
present evidence suggesting a unified model whereby RPAP1 operates by 488 
coordinating the communication between Mediator and RNA Pol II, particularly 489 
on super-enhancer-driven genes. 490 
491 
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EXPERIMENTAL PROCEDURES – STAR METHODS 492 
Detailed methods are provided in the online version of this paper and include 493 
the following: 494 
 495 
KEY RESOURCES TABLE 496 
CONTACT FOR REAGENT AND RESOURCE SHARING 497 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 498 
 Mice 499 
 Cells and Culture Conditions 500 
METHOD DETAILS 501 
 CRISPR/Cas9-based gene editing 502 
 Production of Retrovirus and Lentivirus, and infection of recipient cells 503 
 Generation of iPS cells from primary MEFs or i4F-MEFs 504 
 Growth factors and small molecules to improve iPS reprogramming 505 
 Differentiation with retinoic acid 506 
EB Hanging-Drop Differentiation 507 
Wound healing scratch assay 508 
Cytometry 509 
Cell lysis and Western blot 510 
Histopathology and Immunohistochemistry 511 
Immunofluorescence 512 
RNA Pol II interactome analysis and LC/LC Mass Spectrometry 513 
Immunoprecipitate sample preparation for Mass Spectrometry. 514 
LC−MS/MS Analysis 515 
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Protein Pol II-interactome Data Collection and Analysis 516 
Protein Pol II-interactome Functional analysis 517 
RNA isolation and Quantitative real-time PCR (qPCR) 518 
RNA-seq transcriptomic analyses 519 
Functional analyses of differential gene expression 520 
Supervised Network Analysis 521 
Comparison of differential gene expression with the iPS roadmap 522 
Conversion of Plant gene expression data to Mammalian homologs 523 
Chromatin Immunoprecipitation (ChIP) and deep-sequencing 524 
Pol II ChIP-seq data analyses 525 
Definition of MEF super-enhancers, their target genes, and eRNA levels 526 
 527 
QUANTIFICATION AND STATISTICAL ANALYSIS 528 
DATA AND SOFTWARE AVAILABILITY 529 
 Data Resources: Accession numbers. 530 
 531 
 532 
SUPPLEMENTAL INFORMATION 533 
 534 
Supplemental Information includes 5 Supplemental Figures, 6 Supplemental 535 
tables, and Supplemental Experimental Procedures in STAR METHODS. 536 
RNA Pol II regulator RPAP1 and cell identity   26 
   
Lynch et al., submitted  26 	
AUTHOR CONTRIBUTIONS 
 
C.J.L. performed most of the experiments, contributed to experimental design, 
data analysis, and co-wrote the manuscript; R.B., I.C., S.N.P., S.R., and N.I., 
contributed to experimental work; C.J.L., A.M.D.V., O.G., G.G. and E.A.L. 
contributed to bioinformatic analyses; V.E.A. and A.D.S performed supervised 
network analyses; S.O. performed blastocyst injections; E.R., O.F.C., and J.M., 
provided reagents, discussion, and revisions.  M.S. designed and supervised 
the study, secured funding, analyzed the data, and co-wrote the manuscript.  All 
authors discussed the results and commented on the manuscript. 
 
ACKNOWLEDGMENTS 
 
We are grateful to Elisa Varela for assistance with morula and blastocyst 
fixation.  Work in the laboratory of M.S. is funded by the CNIO and the IRB and 
by grants from the Spanish Ministry of Economy co-funded by the European 
Regional Development Fund (SAF project), the European Research Council 
(ERC Advanced Grant), the Regional Government of Madrid co-funded by the 
European Social Fund (ReCaRe project), the European Union (RISK-IR 
project), the Botin Foundation and Banco Santander (Santander Universities 
Global Division), the Ramon Areces Foundation, and the AXA Foundation.  The 
funders had no role in study design, data collection and analysis, decision to 
publish, or preparation of the manuscript. 
 
RNA Pol II regulator RPAP1 and cell identity   27 
   
Lynch et al., submitted  27 	
REFERENCES 
 
Allen, B.L., and Taatjes, D.J. (2015). The Mediator complex: a central integrator 
of transcription. Nat. Rev. Mol. Cell Biol. 16, 155–166. 
Allepuz-Fuster, P., Martinez-Fernandez, V., Garrido-Godino, A.I., Alonso-
Aguado, S., Hanes, S.D., Navarro, F., and Calvo, O. (2014). Rpb4/7 facilitates 
RNA polymerase II CTD dephosphorylation. Nucleic Acids Res. 42, 13674–
13688. 
Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, 
M., Chen, Y., Zhao, X., Schmidl, C., Suzuki, T., et al. (2014). An atlas of active 
enhancers across human cell types and tissues. Nature 507, 455–461. 
Arner, E., Daub, C.O., Vitting-Seerup, K., Andersson, R., Lilje, B., Drablos, F., 
Lennartsson, A., Ronnerblad, M., Hrydziuszko, O., Vitezic, M., et al. (2015). 
Transcribed enhancers lead waves of coordinated transcription in transitioning 
mammalian cells. Science (80-. ). 347, 1010–1014. 
Boulon, S., Pradet-Balade, B., Verheggen, C., Molle, D., Boireau, S., 
Georgieva, M., Azzag, K., Robert, M.C., Ahmad, Y., Neel, H., et al. (2010). 
HSP90 and its R2TP/Prefoldin-like cochaperone are involved in the cytoplasmic 
assembly of RNA polymerase II. Mol. Cell 39, 912–924. 
Chen, F.X., Woodfin, A.R., Gardini, A., Rickels, R.A., Marshall, S.A., Smith, 
E.R., Shiekhattar, R., and Shilatifard, A. (2015). PAF1, a Molecular Regulator of 
Promoter-Proximal Pausing by RNA Polymerase II. Cell 162, 1003–1015. 
Cheng, B., Li, T., Rahl, P.B., Adamson, T.E., Loudas, N.B., Guo, J., Varzavand, 
K., Cooper, J.J., Hu, X., Gnatt, A., et al. (2012). Functional Association of 
Gdown1 with RNA Polymerase II Poised on Human Genes. Mol. Cell 45, 38–
50. 
Corbi, N., Di Padova, M., De Angelis, R., Bruno, T., Libri, V., Iezzi, S., Floridi, 
A., Fanciulli, M., and Passananti, C. (2002). The a-like RNA polymerase II core 
subunit 3 (RPB3) is involved in tissue-specific transcription and muscle 
differentiation via interaction with the myogenic factor myogenin. FASEB J. 16, 
1639–1641. 
D’Alessio, J.A., Wright, K.J., and Tjian, R. (2009). Shifting Players and 
Paradigms in Cell-Specific Transcription. Mol. Cell 36, 924–931. 
Davis, J.A., Takagi, Y., Kornberg, R.D., and Asturias, F.J. (2002). Structure of 
the yeast RNA polymerase II holoenzyme: Mediator conformation and 
polymerase interaction. Mol. Cell 10, 409–415. 
Egloff, S., Zaborowska, J., Laitem, C., Kiss, T., and Murphy, S. (2012a). Ser7 
phosphorylation of the CTD recruits the RPAP2 ser5 phosphatase to snRNA 
genes. Mol. Cell 45, 111–122. 
Egloff, S., Dienstbier, M., and Murphy, S. (2012b). Updating the RNA 
polymerase CTD code: Adding gene-specific layers. Trends Genet. 28, 333–
341. 
RNA Pol II regulator RPAP1 and cell identity   28 
   
Lynch et al., submitted  28 	
Factor, D.C., Corradin, O., Zentner, G.E., Saiakhova, A., Song, L., Chenoweth, 
J.G., McKay, R.D., Crawford, G.E., Scacheri, P.C., and Tesar, P.J. (2014). 
Epigenomic comparison reveals activation of “seed” enhancers during transition 
from naive to primed pluripotency. Cell Stem Cell 14, 854–863. 
Forget, D., Lacombe, A.-A., Cloutier, P., Al-Khoury, R., Bouchard, A., Lavallee-
Adam, M., Faubert, D., Jeronimo, C., Blanchette, M., and Coulombe, B. (2010). 
The Protein Interaction Network of the Human Transcription Machinery Reveals 
a Role for the Conserved GTPase RPAP4/GPN1 and Microtubule Assembly in 
Nuclear Import and Biogenesis of RNA Polymerase II. Mol. Cell. Proteomics 9, 
2827–2839. 
Forget, D., Lacombe, A.A., Cloutier, P., Lavallée-Adam, M., Blanchette, M., and 
Coulombe, B. (2013). Nuclear import of RNA polymerase II is coupled with 
nucleocytoplasmic shuttling of the RNA polymerase II-associated protein 2. 
Nucleic Acids Res. 41, 6881–6891. 
Gaillochet, C., and Lohmann, J.U. (2015). The never-ending story: from 
pluripotency to plant developmental plasticity. Development 142, 2237–2249. 
Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., 
Lucau-Danila, A., Anderson, K., André, B., et al. (2002). Functional profiling of 
the Saccharomyces cerevisiae genome. Nature 418, 387–391. 
Hansson, J., Rafiee, M.R., Reiland, S., Polo, J.M., Gehring, J., Okawa, S., 
Huber, W., Hochedlinger, K., and Krijgsveld, J. (2012). Highly Coordinated 
Proteome Dynamics during Reprogramming of Somatic Cells to Pluripotency. 
Cell Rep. 2, 1579–1592. 
Hazbun, T.R., Malmström, L., Anderson, S., Graczyk, B.J., Fox, B., Riffle, M., 
Sundin, B.A., Aranda, J.D., McDonald, W.H., Chiu, C.-H., et al. (2003). 
Assigning function to yeast proteins by integration of technologies. Mol. Cell 12, 
1353–1365. 
Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-André, V., Sigova, A.A., 
Hoke, H.A., and Young, R.A. (2013). Super-enhancers in the control of cell 
identity and disease. Cell 155. 
Hsin, J.-P., and Manley, J.L. (2012). The RNA polymerase II CTD coordinates 
transcription and RNA processing. Genes Dev. 26, 2119–2137. 
Hu, X., Malik, S., Negroiu, C.C., Hubbard, K., Velalar, C.N., Hampton, B., 
Grosu, D., Catalano, J., Roeder, R.G., and Gnatt, A. (2006). A Mediator-
responsive form of metazoan RNA polymerase II. Proc. Natl. Acad. Sci. 103, 
9506–9511. 
Ito, T., Chiba, T., Ozawa, R., Yoshida, M., Hattori, M., and Sakaki, Y. (2001). A 
comprehensive two-hybrid analysis to explore the yeast protein interactome. 
Proc. Natl. Acad. Sci. U. S. A. 98, 4569–4574. 
Jeronimo, C., Langelier, M.-F., Zeghouf, M., Cojocaru, M., Bergeron, D., Baali, 
D., Forget, D., Mnaimneh, S., Davierwala, A.P., Pootoolal, J., et al. (2004). 
RPAP1, a novel human RNA polymerase II-associated protein affinity purified 
with recombinant wild-type and mutated polymerase subunits. Mol. Cell. Biol. 
RNA Pol II regulator RPAP1 and cell identity   29 
   
Lynch et al., submitted  29 	
24, 7043–7058. 
Jeronimo, C., Forget, D., Bouchard, A., Li, Q., Chua, G., Poitras, C., Thérien, 
C., Bergeron, D., Bourassa, S., Greenblatt, J., et al. (2007). Systematic analysis 
of the protein interaction network for the human transcription machinery reveals 
the identity of the 7SK capping enzyme. Mol. Cell 27, 262–274. 
Jishage, M., Malik, S., Wagner, U., Uberheide, B., Ishihama, Y., Hu, X., Chait, 
B.T., Gnatt, A., Ren, B., and Roeder, R.G. (2012). Transcriptional regulation by 
pol II(G) involving mediator and competitive interactions of gdown1 and tfiif with 
pol II. Mol. Cell 45, 51–63. 
Kagey, M.H., Newman, J.J., Bilodeau, S., Zhan, Y., Orlando, D.A., van Berkum, 
N.L., Ebmeier, C.C., Goossens, J., Rahl, P.B., Levine, S.S., et al. (2010). 
Mediator and cohesin connect gene expression and chromatin architecture. 
Nature 467, 430–435. 
Levine, M. (2011). Paused RNA Polymerase II as a Developmental Checkpoint. 
Cell 145, 502–511. 
Li, T., and Price, D.H. (2012). Gdown1. Transcription 3, 177–180. 
Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., He, W., Chen, J., Li, F., 
Zhuang, Q., et al. (2010). A mesenchymal-to-Epithelial transition initiates and is 
required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 7, 
51–63. 
Li, W., Notani, D., and Rosenfeld, M.G. (2016). Enhancers as non-coding RNA 
transcription units: recent insights and future perspectives. Nat. Rev. Genet. 17, 
207–223. 
Lin, C.Y., Lovén, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, 
T.I., and Young, R.A. (2012). Transcriptional amplification in tumor cells with 
elevated c-Myc. Cell 151, 56–67. 
Liu, X., Kraus, W.L., and Bai, X. (2015). Ready, pause, go: Regulation of RNA 
polymerase II pausing and release by cellular signaling pathways. Trends 
Biochem. Sci. 40, 516–525. 
Meyerowitz, E.M. (2002). Plants Compared to Animals: The Broadest 
Comparative Study of Development. Science (80-. ). 295, 1482–1485. 
Mosley, A.L., Pattenden, S.G., Carey, M., Venkatesh, S., Gilmore, J.M., 
Florens, L., Workman, J.L., and Washburn, M.P. (2009). Rtr1 Is a CTD 
Phosphatase that Regulates RNA Polymerase II during the Transition from 
Serine 5 to Serine 2 Phosphorylation. Mol. Cell 34, 168–178. 
Muñoz, A., Mangano, S., González-García, M.P., Contreras, R., Sauer, M.B., 
De Rybel, B., Weijers, D., Sánchez-Serrano, J.J., Sanmartín, M., and Rojo, E. 
(2017). RIMA-dependent nuclear accumulation of IYO triggers auxin-irreversible 
cell differentiation in Arabidopsis. Plant Cell 29, tpc.00791.2016. 
Polo, J.M., Anderssen, E., Walsh, R.M., Schwarz, B.A., Nefzger, C.M., Lim, 
S.M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., et al. (2012). A 
molecular roadmap of reprogramming somatic cells into iPS cells. Cell 151, 
1617–1632. 
RNA Pol II regulator RPAP1 and cell identity   30 
   
Lynch et al., submitted  30 	
Rahl, P.B., Lin, C.Y., Seila, A.C., Flynn, R.A., McCuine, S., Burge, C.B., Sharp, 
P.A., and Young, R.A. (2010). C-Myc regulates transcriptional pause release. 
Cell 141, 432–445. 
van Riggelen, J., Yetil, A., and Felsher, D.W. (2010). MYC as a regulator of 
ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10, 301–309. 
Sanmartín, M., Sauer, M., Muñoz, A., Zouhar, J., Ordóñez, A., Van De Ven, 
W.T.G., Caro, E., De La Paz Sánchez, M., Raikhel, N. V., Gutiérrez, C., et al. 
(2011). A molecular switch for initiating cell differentiation in arabidopsis. Curr. 
Biol. 21, 999–1008. 
Sanmartín, M., Sauer, M., Muñoz, A., and Rojo, E. (2012). Lifting the roadblock 
to differentiation © 2012 Landes Bioscience . © 2012 Landes Bioscience . 25–
28. 
Savatier, P., Lapillonne, H., van Grunsven, L.A., Rudkin, B.B., and Samarut, J. 
(1996). Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor 
up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse 
embryonic stem cells. Oncogene 12, 309–322. 
Thiery, J.P., Acloque, H., Huang, R.Y.J., and Nieto, M.A. (2009). Epithelial-
Mesenchymal Transitions in Development and Disease. Cell 139, 871–890. 
Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., 
Rahl, P.B., Lee, T.I., and Young, R.A. (2013). Master transcription factors and 
mediator establish super-enhancers at key cell identity genes. Cell 153, 307–
319. 
Wild, T., and Cramer, P. (2012). Biogenesis of multisubunit RNA polymerases. 
Trends Biochem. Sci. 37, 99–105. 
 
 
 
 
 
 
 
RNA Pol II regulator RPAP1 and cell identity   31 
   
Lynch et al., submitted  31 	
FIGURE LEGENDS 
 
Figure 1.  RPAP1 expression, localisation, and requirement for survival in 
stem cells versus differentiated cells.  See also Figure S1. 
(A,B) Western blot of RPAP1 expression in a range of pluripotent cell types 
versus adult tissues (A), or MEFs (B). 
(C) Western blot of RPAP1 expression and the ES marker NANOG during a 
timecourse of ES cell differentiation by LIF-removal and retinoic acid 
addition. 
(D) Immunohistochemical and Immunofluorescence staining for RPAP1 in 
mouse E3.0 morula (upper panel) or E4.0 blastocyst (lower panel).  Scale 
bars are 20 µm. 
(E-G) Immunofluorescence for RPAP1.  (E) ES cells undergoing self-renewal 
versus 24 hrs differentiation by LIF-removal.  (F) ES cells exposed to 
Leptomycin B for 3 hrs.  (G) MEFs at day 3 after lentiviral shRNA with non-
targeting control (shSCR) or for RPAP1 depletion (shRPAP1). 
(H) Immunohistochemical staining for RPAP1 in mouse adult testis.  Scale bar 
30 µm. 
(I) ChIP-qPCR for Pol II or RPAP1 enrichment at promoters of the indicated 
genes.  Analysis was performed on ES cells maintained in self-renewal 
conditions, or after 24 hrs of differentiation by LIF withdrawal and addition 
of Retinoic Acid (Diff).  See Table S6 for ChIP-qPCR primers. 
(J) Quantification of apoptosis by AnnexinV/propidium iodide co-staining and 
FACS of the indicated cell lines at day 6 after lentiviral control (shSCR) or 
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RPAP1 depletion (shRPAP1).  Mean+/-SEM, n=3 replicates; *p<0.05, 
**p<0.01. 
(K) Proliferation curves (shown by cumulative population doubling) treated by 
control (shSCR) or lentiviral shRNA against RPAP1 in the indicated cell 
lines. 
 
Figure 2.  RPAP1 is required for the establishment and maintenance of 
cell identity.  See also Figure S2. 
(A) Effect of RPAP1 depletion on Embryoid Body (EB) cardiac centre 
development.  EBs were scored daily by microscopy for the appearance of 
clusters of actively-beating cells indicative of cardiac muscle development.  
The graph shows the kinetics of this development over several days.  
Representative pictures of EBs are shown. 
(B) qPCR analyses of pluripotency or cardiac development markers at the 
indicated time points from the EB differentiation assay in (A).  Mean+/-SD, 
n=3 replicates; *p<0.05. 
(C) Overview of RNA-seq transcriptome analyses summarizing differential 
gene expression (FDR q<0.05) in MEFs at day 3 after RPAP1 depletion.  
Upper panel: Proportional representation pie-chart of significantly 
differentially expressed genes.  Lower panel: dot plot of FPKM values for 
all genes, showing that many genes of high and low expression level 
remain unchanged. 
(D) Ingenuity Pathway Analysis showing the top 25 most significantly enriched 
GO terms amongst those genes which were significantly downregulated at 
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day 3 after RPAP1 depletion in MEFs (FDR q<0.01).  Terms highlighted in 
red contain “development” or “morphogenesis”.  Dotted line indicates the 
basal threshold of significance. 
(E) Examples of the most significantly up- or downregulated genesets 
identified by GSEA analysis in RNA-seq data at day 3 after RPAP1 
depletion in MEFs (FDR q<0.01).  See also Figures S3J, S3K; and Table 
S2. 
(F) qPCR validation of RNA-Seq data.  Mesenchymal, fibroblast, and 
epithelial marker mRNA expression levels were assessed by RNA-Seq 
(left) or qPCR (right) at day 3 after RPAP1-knockdown in MEFs.  Data 
indicates fold change relative to control shSCR, Mean +/-SD, n= 3 
independent MEF lines; *p<0.05. 
(G) qPCR measurement of mesenchymal and fibroblast marker mRNA levels 
during days 1-3 after lentiviral control (shSCR) or RPAP1 depletion 
(shRPAP1) in MEFs.  Data indicates fold change relative to control, Mean 
+/- SD, n=3 independent MEF lines; *p<0.05.  See also Figure S2L. 
(H) Heatmap summarizing the most significantly up- or downregulated 
hallmark genesets identified by GSEA analysis amongst all gene 
expression at day 3 after RPAP1 depletion in MEFs (FDR q<0.01; left 
column; see Tables S2 and S3), or in ES cells 24hrs after triggering 
differentiation (FDR q<0.05; right column see Tables S1 and S2).  
Hallmark genesets with FDR q<0.25 are significant.  Also highlighted in 
the heatmap are borderline genesets (where FDR q = 0.35-0.25). 
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(I) Wound assay scratch test recovery.  Graph shows the percent damaged 
area remaining at +24hrs.  Mean +/- SD, n=3 independent MEF lines with 
12 replicates each; *p<0.05. 
 
Figure 3.  RPAP1-knockdown favors de-differentiation and reprogramming 
See also Figure S3. 
(A) Comparison of gene expression at day 3 after RPAP1 depletion in MEFs, 
versus, a published iPS roadmap gene expression profile (Polo et al., 
2012).  Panels show GSEA comparison of the published top 500 genes 
up-or downregulated at day 3 of the iPS roadmap, versus, a ranked list of 
the gene expression profile in the current study at day 3 after RPAP1 
depletion in MEFs (x-axis).  See Methods for assessment of the iPS 
Roadmap data from parental MEFs verses Thy1-negative cells at day 3 
of iPS reprogramming.  FDR q<0.25 are significant.  See also Figures 
S3A and S3B. 
(B) qPCR measurement of selected genes at day 3 after RPAP1 depletion in 
MEFs. Downregulation of Meox1 and Meox2, and, upregulation of 
Nup210, were reported to correlate with cell gene expression during the 
intermediate stages of iPS reprogramming (Hansson et al., 2012; Polo et 
al., 2012).  Mean +/-SD, n= 3 independent MEF lines; *p<0.05; **p<0.01. 
(C,D) MEF to iPS reprogramming after RPAP1 depletion.  Expression of the 
OSKM reprogramming factors was initiated at day 2 after lentiviral control 
(shSCR) or RPAP1 depletion (shRPAP1).  In (C), top panel: kinetics of iPS 
colony appearance during doxycyclin-induced reprogramming of i4F MEFs 
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which express the four Yamanaka factors (see: Experimental Procedures). 
A profile representative of three independent i4F MEF lines is shown 
(Mean +/-SD, 3 technical replicates).  In (C), bottom panel: quantification 
of iPS colony yield at day 14 of doxycyclin-induced 4F-reprogramming.  
Mean +/-SD, n= 3 independent MEF lines; **p<0.01.  In (D), examples of 
Alkaline Phosphatase staining to indicate iPS colonies formed at day 12 of 
i4F-MEF doxycyclin-induced-OSKM iPS reprogramming (top panel), or 
retroviral delivery of the OSKM factors (bottom panel).  FGF2 was added 
to stimulate reprogramming efficiency. 
(E) Summary of outcomes from 32 combinations of OSKMN Yamanaka 
transcription factors.  Sox2-eGFP MEFs at day 2 after control or RPAP1 
depletion received the indicated factors by retroviral delivery, followed by 
culture in standard iPS reprogramming media.  Progress of iPS 
reprogramming was assessed by cell proliferation rate, morphology 
changes, colony formation, staining for alkaline phosphatase, SSEA1 
expression, and Sox2-eGFP levels.  Sox2-eGFP-positive cells forming 
typical iPS colonies were scored as successfully reprogrammed iPS cells.  
Rapidly proliferating cells which initiated colony formation, and which were 
positive for alkaline phosphatase and SSEA1, but negative for Sox2-
eGFP, were scored as putative intermediate-stages of reprogramming. 
 (F) Examples of Alkaline Phosphatase staining to indicate formation rates of 
iPS colonies and putative intermediate cell types at day 14 of MEF 
reprogramming with the indicated combinations of Yamanaka factors +/- 
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RPAP1 depletion.  Green dot indicates those combinations which 
produced Sox2-eGFP-positive full reprogrammed iPS colonies. 
(G) qPCR measurement of mesenchymal, epithelial and pluripotency marker 
mRNA expression levels.  Data was converted to heatmap format to 
highlight the intermediate nature of marker expression displayed by the 
cells which were generated by shRPAP1+Klf4/cMyc. 
 
Figure 4. RPAP1 regulates the Pol II interactome, not its expression or 
localization.  See also Figure S4. 
(A) Western blots of Pol II Total (RPB1), Ser5P or Ser2P expression in whole 
cell lysates from a range of cell lines at day 3 after RPAP1 depletion.  
GAPDH, b-ACTIN, and LAMIN A/C used as internal controls. 
(B) Western blots of Pol II Total (RPB1), Ser5P, or Ser2P expression in 
Nuclear/Cytoplasmic fractions from a range of cell lines at day 3 after 
RPAP1 depletion.  GAPDH and LAMIN A/C used as indicators of fraction 
separation.  N, Nuclear fraction. C, Cytoplasmic fraction. 
(C) Immunofluorescence of Pol II Total (RPB1), Ser5P or Ser2P in MEFs at 
day 3 after lentiviral control (shSCR) or RPAP1 depletion (shRPAP1).  
Nuclei stained with DAPI. 
(D) Schematic of the 294 specific interactors of Polr2a/RPB1 detected in 
primary MEFs in this study by Pol II immunoprecipitation and mass 
spectrometry analysis (see also: Table S4).  Interactors were displayed as 
a network using Cytoscape, and grouped manually by their known 
physical interactions and general primary function, wherein the thickness 
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and intensity of the connecting edges indicates the strength of their known 
interactions in the STRING database. Following RPAP1-depletion, the Pol 
II-interactors reduced (circled in red) and Pol II-interactors gained (circled 
in green) are indicated.  The Mediator complex is depicted centrally and in 
full colour based on the data in Figure 4E, below. 
(E) Pol II interactors which were decreased following RPAP1 depletion were 
assigned to all 3,000 known protein complexes in the Corum database 
(see Methods).  On left, complexes are ranked according to the highest 
percentage of proteins whose interaction were decreased upon RPAP1-
depletion from the cells.  On right, the total number of subunits per 
complex is indicated, together with the number of subunits detected in this 
study and the number of subunits decreased following RPAP1 depletion. 
 
Figure 5. RPAP1 is required for Pol II transcription in MEFs, particularly on 
developmental and mesenchymal genes. See also Figure S5. 
(A,B) ChIP-Seq enrichment data plotted as heatmaps of Pol II total (A), or Pol 
II Ser5P (B), occupancy around the TSS region +/- 5Kb. Rows are sorted 
by decreasing Pol II occupancy at the promoter (–100 to +300bp) in the 
shSCR control.  Color-scaled intensities are in units of reads per million 
mapped reads (rpm; see Methods – ChIP-seq analysis). 
(C) Proportional representation of ChIP data, classifying genes according to 
the changes in abundance of Pol II total (upper panel) or Ser5P (lower 
panel) at the promoter (–100 to +300bp), following RPAP1 depletion in 
MEFs for 3 days. 
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(D) Schematics of Pol II total and Ser5P abundance on selected genes, 
showing examples of Pol II depletion (S100a4, Snai1, Snai2) or minimal 
effects (Asap3, Tulp3). 
(E) Table summarizing the most significantly up- or downregulated GO-term 
genesets identified by GSEA among the genes with >2xfold decrease in 
Pol II following RPAP1 depletion in MEFs, (see also: Tables S2 and S5).  
Genesets with FDR q-value <0.25 are significant. 
(F) Summary heatmap displaying the overlay of significant GSEA hallmark 
genesets across 4 experiments (Columns 1 and 2: see also Figure 2H). 
Column 1: GSEA on the ranked list of differential mRNA expression in 
MEFs at day 3 +/- RPAP1-depletion.  Column 2: GSEA on the ranked list 
of differential mRNA expression in ES cells at +24hrs after inducing 
differentiation, +/- RPAP1-depetion.  Column3: GSEA on the ranked list of 
differential Pol II abundance at all promoters in MEFs at day 3 +/- RPAP1 
depletion.  Column4: GSEA on the ranked list of differential gene 
expression in Arabidopsis thaliana plant tissues +/- RPAP1-mutation 
(Sanmartín et al., 2011), following conversion to the nearest mouse 
homolog based on protein sequence conservation (see: Methods – 
Conversion of Plant to Mouse homologs, and Table S2). 
(G) GSEA to assess mRNA expression levels of MEF super-enhancer target 
genes (n= 661, defined by GREAT analysis as described, see Methods) 
within the transcriptome of primary MEFs at day3 after RPAP1 
knockdown. Compare with Housekeeper gene expression in Figure S5G. 
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(H) Plots show the average eRNA levels within two groups of MEF super-
enhancers regions: those which were increased (n=63 enhancers, top 
panel) or decreased (n=64 enhancers, bottom panel) in MEFs at day 3 
after RPAP1 knockdown. 
(I) GREAT analysis was used to identify a set of target genes for each of the 
two super-enhancer groups identified in (H) (see: Methods).  Next, the 
developmental stages significantly associated with the enhancer-target 
genes in each group were identified and plotted according to their group, 
that is whether the associated enhancer had increased or decreased 
eRNA abundance, in MEFs at day 3 after RPAP1 knockdown.  See also, 
Figures S5H to S5I for tables of functions and developmental stages 
enriched within the target genes of enhancers identified in (H) above. 
(J,K) Model for RPAP1 function in the mechanism for triggering development.  
(J) In self-renewing ES cells, RPAP1 is expressed but largely inhibited 
from interacting with Pol II, being continuously imported and exported from 
the nucleus such that it is predominantly cytoplasmic in its overall 
abundance.  Upon differentiation, nuclear accumulation of RPAP1 permits 
increased transcriptional regulation.  Hence, depletion of RPAP1 in self-
renewing ES cells does not affect proliferation or pluripotency, however 
ES cell differentiation is aberrant.  Depletion of RPAP1 in MEFs, where it 
is nuclear, results in Pol II transcriptional dysfunction preferentially on cell 
identity and developmental regulator genes, which is associated with de-
differentiation and enhanced susceptibility for reprogramming towards 
pluripotency.  (K): Taken together, our data suggest a model where 
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RPAP1 exists in complex with RNA Pol II, and plays an essential role in 
the Mediator-Pol II regulatory axis.  Thus, loss of RPAP1 triggers a 
decrease in the association between Mediator and Pol II (including the key 
regulators Gdown1 (G) and the Ser5P phosphatase RPAP2) preferentially 
affecting the ability of enhancers to activate Mediator target genes, which 
are known to include the key markers and regulators of cell identity.  In 
somatic cells such as MEFs, this leads to de-differentiation, as expression 
of fibroblastic, mesenchymal and developmental markers is erased. 
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	Supplemental Figure S1. Related to Figure 1. 
RPAP1 expression, localisation, and requirement for survival in stem cells 
versus differentiated cells. 
(A) Western blot of RPAP1 expression during a timecourse of P19EC cell 
differentiation by Retinoic Acid addition. 
(B) Immunohistochemical staining for RPAP1 in mouse E13.5 liver, adult 
ovary, and adult skin.  Scale bars represent 30 µm. 
(C) Western blot of RPAP1 expression in mouse ES cells at day 6 following 
five separate lentiviral shRNA against RPAP1 (#1-#5). 
(D) Photographs of the indicated cell lines at days 6-9 after lentiviral control 
(shSCR) or RPAP1 depletion (shRPAP1). 
(E) Quantification of senescence-associated b-galactosidase staining in MEFs 
at day 9 after lentiviral control (shSCR) or RPAP1 depletion (shRPAP1).  
Mean+/-SD, n=3 replicates; **p<0.01. 
(F) Proliferation curves (shown by cumulative population doubling) following 
lentiviral control (shSCR) or RPAP1 depletion (shRPAP1) in 293T cells 
using 3 different shRNAs. 
(G) Proliferation curves (shown by cumulative population doubling) following 
lentiviral control (shSCR) or RPAP1 depletion (shRPAP1) in the indicated 
cell lines. 
(H) FACS analysis of a Nanog-GFP reporter ES cell line (TNGA) cultured in 
three different media cocktails, at day 6 after lentiviral control (shSCR) or 
RPAP1 depletion (shRPAP1). Wild type non-GFP ES cells were used as 
negative control. 
	(I) Schematic of the 26-Exon mouse RPAP1 gene (Gene ID: 68925; 
NM_177294.5).  Indicated are: the open reading frame ATG start (green, 
exon3) and TGA stop (red, exon26); the location of the gene trap in 
CSI619 ES cells (grey, intron8); and the location of CRISPR guide RNAs 
used in this study (blue, exons 3-7; see also: Table S6).  Table (below) 
summarizes the effect of multiple CRISPR approaches on the expression 
of RPAP1.  While RPAP1 protein levels were decreased in cell pools and 
in clonal lines, no RPAP1-null clones could be derived. 
(J) Example of Western blot analyses of whole population from haploid HAP1 
cells following CRISPR against RPAP1 using lentiviral constitutive 
CRISPR/Cas9 expression. 
(K) Examples of Western blot analyses of ES clones following CRISPR 
against RPAP1 using CRISPR/Cas9 expression systems which were 
transient in wild-type E14 ES cells (pX330; above), or constitutive in G4 
ES cells (lentiviral; below). 
(L) CSI619 (RPAP1+/Trap) reporter ES cells stained for LacZ 3 days after 
CRISPR against RPAP1.  Inset shows examples of ES colonies expanded 
from single cells and stained for LacZ (blue) expressed from the RPAP1 b-
geo reporter allele.  Arrow: a white/non-stained colony, indicating that 
CRISPR has successfully mutated at least one of the RPAP1 alleles, by 
knocking out the RPAP1 b-geo reporter allele.  Bar chart below, shows the 
percentage of non-staining colonies at Days +3 or +10 after CRISPR in 
the whole population.  Significantly fewer non-staining colonies are 
observed at Day+10 (after a passage).  This suggests that where CRISPR 
	is active, and also knocks out the WT RPAP1 allele, the ES cells display a 
growth or survival phenotype within a few days. 
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	Supplemental Figure S2.  Related to Figure 2. 
RPAP1 is required for the establishment and maintenance of cell identity.  
(A) Following shRNA-knockdown of RPAP1, ES cells were differentiated for 
24 hours by LIF-removal, then fixed and scored per colony for morphology 
and Alkaline Phosphatase staining intensity.  Photographs show examples 
of the delay in colony morphology changes and delay in attenuation of AP-
staining intensity associated with RPAP1-depletion at +24 hours after LIF-
removal.  Mean+/-SEM, n=3 replicates; *p<0.05. 
(B) FACS analyses for apoptosis levels by AnnexinV/Propidium Iodide double-
staining in ES cells following induction of differentiation by LIF-removal for 
24 hrs and then addition of retinoic-acid for 48hrs. 
(C) qPCR analyses of pluripotency or cardiac development markers at the 
indicated time points from the EB differentiation assay in Figure 2A.  
Mean+/-SD, n=3 replicates; *p<0.05. Panel on right: Western blot 
confirming RPAP1 knockdown in ES cells during self renewal. 
(D) On left, table summarizing the generation of chimeric mice using CSI619, 
RPAP1(+/Trap) ES cells (1 wild-type and 1 null allele).  A low percentage 
of chimeric pups survived to birth (21/254 micro-injected embryos), of 
which 10/21 pups displayed moderate chimerism based on coat colour 20-
60% Agouti coat colour).  On right, table summarizing the offspring 
generated by mating chimeric mice with eachother, or with wild-type mice, 
to look for germline transmission.  Of 156 pups born from these matings, 7 
pups had Agouti coat colour, indicating that the parental RPAP1(+/Trap) 
ES cells were viable.  However, no pups carried the RPAP1(+/Trap) 
	geneotype, suggesting that a single RPAP1 allele was insufficient for 
germline transmission. 
(E) Overview of differential gene expression in RNA-Seq transcriptome 
analysis of ES cells following RPAP1-knockdown then differentiation for 24 
hours, as above, in Figure S2A.  Proportional representation pie-chart 
indicates the proportion of mRNAs significantly up- or down-regulated with 
FDR q<0.05.  See also Table S1. 
(F,G) Table summarizing the most significantly up- or downregulated Hallmark 
genesets (F), or GO-term genesets (G), identified by GSEA analysis in 
RPAP1-depleted ES cells after 24 of differentiation, as above, in 
FigureS2A (FDR q<0.05; see also Tables S1 and S2).  Genesets with 
FDR q<0.25 are significant. 
(H) GSEA Leading Edge analysis of the most prevalent genes among those 
GO terms database genesets which were significantly downregulated in 
RPAP1-depleted ES cells after 24 hrs of differentiation, as above, in 
Figure S2A (FDR q<0.05; see also Tables S1 and S2). 
(I) Normalized RNA-seq expression levels of mesenchymal, fibroblastic and 
development markers in RPAP1-depleted ES cells after 24 of 
differentiation, as above, in FigureS2A.  Data based on Mean FPKM 
values, n=3 replicates; * FDR q-value <0.05.  See also Table S1. 
(J) Table summarizing the most significantly up- or down-regulated hallmark 
genesets identified by GSEA analysis of RNA-sea data at day 3 after 
RPAP1 depletion in MEFs (FDR q<0.05; see also Tables S2 and S4).  
Hallmark genesets with FDR q<0.25 are significant. 
	(K) Table summarizing GSEA Leading Edge analysis of the most prevalent 
genes among the genesets which were significantly downregulated at day 
3 after RPAP1 depletion in MEFs (FDR q<0.05; see also Table S6) in a 
comparison versus the GSEA C5 GO terms database. 
(L) qPCR analyses of fibroblastic, mesenchymal and development markers at 
the indicated early time points after RPAP1 shRNA depletion in MEFs,.  
Mean+/-SD, n=3 replicates.  Raw data from Figure 2G is displayed here 
relative to the housekeeper internal control Gapdh (whereas, in Figure 
2G, the data is shown as fold-change, normalized to the shSCR non-
targetiing control). 
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	Supplemental Figure S3.  Related to Figure 3. 
RPAP1-knockdown favors de-differentiation and reprogramming. 
 (A) GSEA comparison of gene expression at day 3 after RPAP1 depletion in 
MEFs, versus, a published iPS roadmap gene expression profile (Polo et 
al., 2012).  See Methods for assessment of the iPS Roadmap data from 
control MEFs versus Thy1-negative cells at day 3, or day 9, of 
reprogramming.  The data here can be compared with Figure 3A.  GSEA 
comparison of the published top 500 genes (on left), or Top 100 genes (on 
right (here, the reduced geneset size was used), up- or down-regulated at 
day 3, or day 9, of the iPS roadmap, versus, a ranked list of the gene 
expression profile at day 3 after RPAP1 depletion in MEFs in the current 
study (x-axis).  FDR q<0.25 are significant. 
(B) GSEA comparison of the significantly up- or down-regulated genes (FDR 
q<0.01) at day 3 after RPAP1 depletion in MEFs, versus, a ranked list of 
the published gene expression profile of the iPS roadmap at day 3, or day 
9 (x-axis) as indicated.  FDR q<0.25 are significant. 
(C) Left: a list of growth factors and small molecule inhibitors, and the 
concentrations used, to test culture media supplementation in relation to 
the iPS reprogramming screen in Figure 3E.  Right: the list of 12 
combinations of the media supplements that were tested. 
(D) Cells resembling putative reprogramming intermediates, which were 
generated by shRPAP1+Klf4/cMyc over-expression (see Figure 3E), were 
expanded to passage 4, then independent clones were analyzed for 
	surface expression of SSEA1 by FACS.  MEFS and ES cells were 
included as negative and positive controls for SSEA1 staining respectively. 
(E) Sox2-eGFP-positive iPS colonies were counted per well at day14 following 
retroviral expression of the indicated combinations of Yamanaka factors, 
RPAP1 depletion, and/or TGFb-signaling inhibition (see: Experimental 
Procedures).  Mean +/-SD, 3 replicates; ***p<0.001, versus the control 
(lane 1). 
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	Supplemental Figure S4.  Related to Figure 4. 
RPAP1 regulates the Pol II interactome, not its expression or localization. 
(A,B) Western blots of RPAP1, Pol II Total (RPB1), Ser5P, or Ser2P 
expression in whole cell lysates from two independent MEF lines at day 3 
(A), or from HEP and H226 cell lines (B), at day 3 after lentiviral control 
(shSCR) or RPAP1 depletion (shRPAP1).  GAPDH, b-ACTIN, and LAMIN 
A/C used as internal loading controls. 
(C) Western blots of Pol II Total (RPB1), Ser5P, or Ser2P expression in 
Nuclear/Cytoplasmic fractions from HEP and H226 cell lines at day 3 after 
RPAP1 depletion.  GAPDH and LAMIN A/C used as indicators of fraction 
separation.  N, Nuclear fraction. C, Cytoplasmic fraction. 
(D) Immunofluorescence of Pol II Total (RPB1), Ser5P or Ser2P in a range of 
human cell lines at day 3 after lentiviral control (shSCR) or RPAP1 
depletion (shRPAP1).  Nuclei stained with DAPI. 
(E) Gene ontology analysis for the enrichment of biological processes among 
the Pol II interactors lost following RPAP1-depletion, with p-value 
corrected for multiple testing (Bonferroni). 
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	Supplemental Figure S5.  Related to Figure 5. 
RPAP1 is required for Pol II transcription in MEFs, particularly on 
developmental and mesenchymal genes.  
(A) GSEA Leading Edge analysis.  The genesets which were significantly 
depleted in Pol II abundance were identified in MEFs at day 3 after RPAP1 
depletion (see Tables S2 and S6; and Figure 5E). The table lists the 
most prevalent genes among the GO term genesets. 
(B) Definition and analysis of Pol II loading ratio on Promoter-Body (or 
Pausing Index, PI).  Schematics outline the parameters used to define the 
whole gene, promoter, gene body, and Pausing Index (PI) in this study, 
(see also Methods).  An example of preferential depletion of Pol II from 
the gene body is shown, in lower panel. 
(C,D) Plots showing the PI ratio for all genes, or all regulators of the Epithelial-
Mesenchymal Transition (defined by the GSEA Hallmark geneset #M5930, 
MySigDB, Broad Institute).  In (D), data are Mean +/- SEM of “n” genes as 
indicated; **p<0.01.  In (C) and (D), at day 3 after RPAP1 depletion in 
MEFs, the Mean PI significantly decreases for many genes (DPI <1.0), 
however, the Mean PI increases for EMT-regulatory genes (DPI >1.0).  
This is consistent with preferential depletion of Pol II from the gene body, 
as depicted in lower panel of (B), above. 
(E) Ratio of shRPAP1/shSCR for the change in PI for each gene (DPI), at day 
3 after lentiviral control (shSCR) or RPAP1 depletion (shRPAP1) in MEFs.  
Arrow highlights the region containing genes with increased PI at their 
promoters.   Table shows the top three GSEA results which identify that 
	genesets and genes with increased pausing index (region highlighted in 
plot) are enriched for MEF cell identity and developmental regulators (FDR 
q<0.25 is significant).  Below: examples of GSEA plots for the most 
significantly enriched genesets with increased PI (see also Table S5 for PI 
calculations per gene, and Table S2 for full GSEA results). 
(F) Graph of the change in Ser5P density comparing shRPAP1/shSCR, at the 
promoter (red), or in the gene body, (black).  Data from day 3 after 
lentiviral control (shSCR) or RPAP1 depletion (shRPAP1) in MEFs.  Arrow 
highlights the region containing genes with increased Pol II Ser5P density 
at their promoters.  GSEA analyses were performed on the entire ranked 
lists for promoters (red line) or the gene bodies (black line), however, 
significant enrichment of genesets was only observed for those genes with 
increased Pol II Ser5P density at their promoters (Red plot line, region as 
indicated by arrow).  Table below shows the top three GSEA results which 
identify that genes with increased promoter Ser5P density (region 
highlighted in red plot line by arrow, above) are enriched for cell identity 
and developmental regulators (FDR q<0.25 is significant).  Below: 
examples of GSEA plots for the most significantly enriched genesets with 
increased Ser5P density at their promoter (see also Table S5 for Ser5P 
density calculations per gene, and Table S2 for full GSEA results). 
(G) GSEA to assess mRNA expression levels of housekeeper genes, (as 
defined: see Methods) in primary MEFs at day3 after RPAP1 knockdown.  
No significant change in housekeeper geneset expression was observed. 
	(H) Developmental stages significantly associated with the super-enhancer 
target genes (P < 10-4) where the enhancers display increased eRNA 
levels in MEFs at day 3 after RPAP1 knockdown. 
(I,J) Developmental stages (I) and GO Biological Processes (J) significantly 
associated with the super-enhancer target genes (P < 10-4) where the 
enhancers display decreased eRNA levels in MEFs at day 3 after RPAP1 
knockdown. 
	SUPPLEMENTAL EXPERIMENTAL PROCEDURES –STAR METHODS 
 
KEY RESOURCES TABLE 
CRISPR gRNAs, Primers, Antibodies and shRNAs used in this study.  See Table S6. 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Please contact Manuel Serrano.  Manuel.serrano@irbbarcelona.org 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice 
Animal experimentation at the CNIO, Madrid, was performed according to protocols approved by the 
CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA). 
 
Cells and Culture conditions 
Primary mouse embryo fibroblasts  (wild-type, MEFs, passage 2) were obtained at E13.5 from pure 
inbred C57BL6 background mice, as described previously (Palmero et al. 2001).  Mouse P19EC cells and 
HEP cells (immortalized mouse hepatocytes), monkey COS7 cells, and the human cell lines 293T, 
HCT116, SCC42B and H226, were from ATCC and were maintained in DMEM medium with 10% FBS 
(Gibco) with antibiotics (penicillin/streptomycin 100 U/ml).  The mouse ES cells E14Tg2a.4 (wild-type 
parental) and CSI619 RPAP1 (+/Trap) mouse ES cells containing a pGT0Lxf genetrap in Intron8 were 
from BayGenomics/MMRRC genetrap resource, University of California.  Nanog-GFP knockin mouse 
ES cells (TNGA) were previously described (Chambers et al., 2007) and were shared by the laboratory of 
Austin Smith.  The	mouse	ES	cells	R1,	G4,	doxy-inducible	ESCas9	as	described	(Ruiz	et	al.,	2016).		HAP1	cells	(a	kind	gift	from	T	Brummelkamp)	were grown in IMDM (Invitrogen) and 15%FBS.	 	The 
Sox2-eGFP MEFS (Sox2-Promoter/GFP transgenic) were as described (D’Amour and Gage, 2003).  
MEFs and P19EC cells were cultured in standard DMEM medium with 10% FBS (Gibco) with 
antibiotics (penicillin/streptomycin 100 U/ml).  Mouse ES cells and iPS cells, were routinely cultured on 
gelatin-coated plates in either “Serum/LIF” (15% FBS), or Knockout Serum Replacement (KSR, 
Invitrogen) “KSR/LIF” (15% KSR), in DMEM (high glucose) basal media, with LIF (1000Units/mL), 
non-essential amino acids, glutamax and beta-mercaptoethanol plus antibiotics.  Where used, the “2i” 
drug cocktail comprised 1 uM Mek-inhibitor (PD0325901, Axon Medchem, #1408) plus 3 uM GSK3b-
inhibitor (CHIR 99021, Axon Medchem #1386) as described (Ying et al., 2008).  Reprogrammed iPS 
cells were initially derived and expanded on mitomycin-C inactivated feeder cells on gelatin-coated 
plates, before transfer to gelatin-only.  Cultures were routinely tested for mycoplasma and were always 
negative.  C57BL/6 ES cells were derived at the Transgenic Mice Unit of the Spanish National Cancer 
Research Center (commonly abbreviated as CNIO, from the name in Spanish: Centro Nacional de 
Investigaciones Oncológicas) from E4.5 C57BL6 blastocysts, or mixed background C57BL6/129 
blastocysts.  ES cell self-renewal and pluripotency was scored, by cytometry (Nanog-GFP heterogeneity 
and overall intensity), by immunofluorescence (see below), by colony morphology (see Figures S1D and 
S2A), by alkaline phosphatase staining of fixed cells (Promega #S3771), and by qPCR for stemness 
markers Nanog, Oct4 and Sox2 (See: Figures 2B and S2C), in addition to their differentiation capacity 
in retinoic acid or embryoid body cardiac centre development (see below).  To inhibit CRM1-dependent 
nuclear export, cells were treated for 3hrs with 10 nM Leptomycin B (Sigma #L2913).  For proliferation 
curves, cells were counted and serially passaged every 3 days to monitor the cumulative doubling rate.  
Senescence-associated b-gal staining was performed as described (Munoz et al., 2013).  Staining for 
LacZ expression in the CSI619 ES cells RPAP1(+/Trap), where the genetrap contains a b-geo reporter, 
was performed as described (Munoz et al., 2013).	
 
 
	METHOD DETAILS 
CRISPR/Cas9-based gene editing 
To target human or mouse RPAP1 sequences, we used the MIT CRISPR design tool (http://tools.genome-
engineering.org) to design the sgRNAs as described (Ran et al., 2013).  Six mouse sgRNAs were used 
targeting mouse/human RPAP1 Exons 4-7 (see Figure S1I) or 4 sgRNAs targeting human RPAP1 Exons 
2-4, either individually to generate indels, or in combinations to generate deleted regions (see: Table S6, 
Sheet#4, for sgRNA sequences, plasmid details and gRNA combinations used).  RPAP1-knockout was 
assessed by Western blot of entire cellular pools, or derivation and expansion of individual clones. 
Briefly, three CRISPR strategies were pursued.  Transient CRISPR/Cas9 expression was by 
electroporation of mouse ES cells (Neon Transfection System; 1200V, 20 msec, 2 pulses) using the 
pX330 plasmid (Addgene #42230).  Constitutive CRISPR/Cas9 expression was by pLentiCRISPRv2 
(Addgene: #52961) as described (Ruiz et al., 2010).  For the human HAP1 cell line, human specific 
CRISPR-sgRNAs oligos (Table S6, Sheet#4) were cloned into the pLenti-CRISPRV2 (Addgene plasmid 
#52961).  For doxycyclin-inducible CRISPR/Cas9: CRISPR-sgRNAs oligos cloned into the pKLV-U6-
gRNA (BbsI)-PGKpuro2ABFP (Addgene #50946) to generate doxy-inducible ESCas9 cells as described 
(Ruiz et al., 2016).  Individual lentiviral vectors pKLV-U6gRNA-PGKpuro2ABFP (Addgene #50946) or 
pLentiCRISPR v2 (Addgene plasmid #52961) were co-transfected with 3rd generation packaging vectors 
in 293T cells using Lipofectamine 2000 (Invitrogen) in order to generate viral supernatants as described 
(Ruiz et al., 2010).  A total of 105 ES cells were infected in suspension with 500 µl of viral supernatant 
for 1 hour at 37ºC and plated on a layer of fresh feeder cells.  Two days after infection, G4 and R1 ES 
cells were selected with Puromycin 1µg/ml and maintained for a week in culture in order to allow 
efficient gene editing.  For the doxycycline-inducible ESCas9 cell line (Ruiz et al, 2016), two days after 
infection, cells were split into media with or without 1 µg/ml doxycycline and maintained for an 
additional week in culture in order to allow efficient gene editing. In the case of Hap1 cells, spinfection 
was used to infect as follows:  a total of 105 HAP1 cells in one 6-well were incubated with 1.5 mls of 
viral supernatant and centrifuged at 1850rpm for 1 hour. Two days after infection, cells were selected 
with Puromycin 1µg/ml and maintained for a week in culture in order to allow efficient gene editing. 
 
Production of Retrovirus and Lentivirus, and infection of recipient cells 
Briefly, retroviral and lentiviral supernatants were produced in HEK-293T cells (5x106 cells per 100-mm-
diameter dish).  Vector transfections were performed using Fugene-6 transfection reagent (Roche) 
according to the manufacturer’s protocol. Two days later, viral supernatants (10 ml) were collected 
serially during the subsequent 48 hours, at 12-hour intervals, each time adding fresh medium to the cells 
(10 ml).  The recipient cells were seeded the previous day (1.5x105 cells per well in a 6-well plate) and 
each well received 1.0 ml of the corresponding retroviral and/or lentiviral supernatants as indicated in 
each Figure.  This procedure was repeated every 12 hours for 2 days (a total of 4 additions).   
 
For lentiviral shRNA production, per dish, 293T cells were  transfected with 3 plasmids:  (i) the ecotropic 
lentiviral envelope packaging plasmid pMD2.G (0.3 µg; Addgene, plasmid #12259; containing the VsVg 
gene); (ii) the lentiviral packaging plasmid pCMV-dR8.91 (3.0 µg); (from: Harvard Medical School, 
plasmid #516); (iii) plus either one of the following 6 lentiviral shRNA constructs (3.0 µg) expressing 
mouse shRNAs against RPAP1 (shRPAP1#1-5, respectively), or the corresponding non-targeting control 
(Scramble, shSCR) vector.  After lentiviral infection was completed, lentiviral RPAP1-knockdown 
shRNA recipient cells were selected with puromycin (1ug/mL).  A panel of five lentiviral shRNA against 
RPAP1 were from Open Biosystems (#RMM4534-NM_177294; TRC Mission Library) with a pLKO.1 
lentiviral backbone.  From these 5 clones we identified that the best knockdown of RPAP1 expression 
was achieved using clone TRCN0000173186, hereafter “shRPAP1#5”.  See shRNA clone details in 
Table S6, sheet#3. 
 
For retrovirus, per dish, 293T cells were transfected with the ecotropic packaging plasmid pCL-Eco (4 
µg) together with one of the following retroviral constructs (4 µg): pMXs-Oct4, pMXs-Sox2, pMXs-Klf4, 
pMXs-cMyc, or pMXs-Nanog (obtained from Addgene and previously described (Takahashi and 
Yamanaka, 2006) -the backbone is pMXs plasmid in all cases and the expression of the coding sequences 
of the reprogramming factors are driven by the MMLV LTR promoter.   
 
Generation of iPS cells from primary MEFs or i4F-MEFs 
For retroviral-mediated iPS reprogramming of primary (passage 2-4) mouse embryo fibroblasts was 
performed by a previous protocol (Li et al., 2009a).  Briefly, after infection of primary MEFs with 
retrovirus expressing the four Yamanaka transcription factors (OSKM), as outlined above, MEF media 
	was replaced by KSR/LIF medium (see above). Cultures were maintained in the absence of drug selection 
with medium changes every 48 hrs (Li et al., 2009a).   
For reprogramming of the secondary-system doxycyclin-inducible 4-Factor (i4F) MEFs which 
inducibly-express the four Yamanaka factors Oct4, Sox2, Klf4, and cMyc (OSKM) was performed as 
previously described (Abad et al., 2013).  Briefly, i4F-MEFs were treated with doxycyclin (1µg/mL) 
continuously to induce expression of the OSKM transcription factors in the presence of the KSR/LIF iPS 
medium described above, which was replaced every 48hrs.. 
After 7-10 days, iPS colonies with ES-like morphology were counted as they became visible and 
were subsequently scored by Alkaline Phosphatase staining according to manufacturer’s protocol (AP 
detection kit, Chemicon International, or, Promega #S3771).  Colonies of iPS cells were picked after 2 
weeks and expanded on feeder fibroblasts using standard procedures.  Sox2-eGFP MEFs (D’Amour and 
Gage, 2003) were used in iPS reprogramming experiments since they become Sox2-GFP-positve 
(reflecting activation of the endogenous pluripotency network) only in the final stages of iPS 
reprogramming (see: Figures 3E, 3F and S3E). 
 
Growth factors and small molecules to improve iPS reprogramming 
The media supplements to improve iPS reprogramming, at the indicated concentrations shown in Figure 
S4C, are as follows: FGF2 (R+D Systems #233-FB/CF); EGF (Sigma # E9644); Alki (SB431542; 
ALK4/5/7 inhibitor; Sigma# #S4317); Forskolin (Sigma # F6886); SCF (R+D Systems #455-MC/CF); 
DLPC (Lrh1 agonist; Stratech # 850335P); 5-Aza-Deoxycitidine (Sigma # A3656-5MG); VPA 
(Calbiochem # 676380);  TSA (Trichostatin A; Sigma; T8552); BIX (BIX 01294; Tocris #3364); 
Kenpaullone (Tocris #1398); Flavopiridol (Santa Cruz # CAS 146426-40-6). 
 
Differentiation with retinoic acid 
Differentiation of ES cells with retinoic acid (RA) was performed essentially as described (Savatier, 
1996).  LIF was first removed for 24 hrs by culture in LIF-free Differentiation medium (that is DMEM 
(high glucose) supplemented with serum 15%, non-essential amino acids, glutamax and beta-
mercaptoethanol; hereinafter referred as "differentiation medium").  Next, LIF-free differentiation media 
was supplemented with Retinoic Acid at 10-6 M from +24 to +72 hrs,followed by LIF-free differentiation 
medium alone from +72 to +96 hrs.  P19EC cell differentiation was by Retinoic Acid addition at 10-6 M. 
 
EB Hanging-Drop Differentiation 
This was performed essentially according to Marikawa et al., 2009.  ES cells were transferred to 
Differentiation medium (that is DMEM (high glucose) supplemented with serum 15%, non-essential 
amino acids, glutamax and beta-mercaptoethanol; hereinafter referred as "differentiation  medium"), and 
suspended in hanging drop culture at a cell density of 5000 cells/20 µLs.  ES cells were allowed to form 
spherical aggregates known as Embryoid Bodies (EBs) for 48 hours in the hanging drops before transfer 
to suspension culture in low-adherence petri-dishes. In suspension culture, fresh Differentiation medium 
was added every 3 days, and the percent of EBs was scored daily for the development of beating cells in 
cardiac centres. 
 
Wound healing scratch assay 
Three MEF clones were assessed for their ability to migrate and close a scratched region at day 3 +/- 
RPAP1 depletion.  Scratch wounds (12 per experimental condition) were made in shSCR and shRPAP1 
cultures and photographed at both +0 and +24 hrs in order to quantify the percent area of the original 
damage which remained at +24 hrs, using ImageJ software analyses of the photographs. 
 
Cytometry 
FACS was performed as described (Li et al 2009a).  Briefly, for SSEA1 analysis, cells were collected by 
scraping and pipetting to unicellularize, before resuspension in 500 µLs 1xPBS and incubation with anti-
SSEA1 antibody conjugated to allophycocyanin (R+D Systems, #FAB2155A) for 15 mins at room 
temperature.  For AnnexinV analysis of apoptosis, the cells were collected by trypsinization before re-
suspension in 1xbinding buffer and incubation with anti-AnnexinV antibody conjugated to FITC (BD 
Pharmingen, # 556570).  Data were analyzed with FlowJo 9.6.2 software.  The percent of cells in S-phase 
was quantified using the Click-iT EdU staining kit (Invitrogen #C35002).  Briefly, cells were exposed to 
EdU in culture for 45 minutes followed by fixation and staining according to the manufacturer’s protocol. 
 
Cell lysis and Western blot 
Whole cell extracts were prepared using 50 mM TrisHCl pH8; 1 mM EDTA; 150 mM NaCl; 1% NP40; 
0.5% Triton X-100; 1.0% SDS, with freshly added protease inhibitors (Roche #11873580001).  A total 
	protein of 10 µg was loaded per lane and resolved on NuPAGE 4-12% gradient Bis-Tris gels, transferred 
to nitrocellulose and hybridized using antibodies as described in Table S6, sheet#2.  Nuclear/Cytosolic 
Fractionation was performed by using the NE-PER Nuclear and Cytoplasmic Extraction Kit by Thermo 
Scientific, following the manufacturer’s instructions. 
 
Histopathology and Immunohistochemistry 
Mouse tissues were fixed in formalin at 4ºC, embedded in paraffin block, and sectioned at a thickness of 
5 µm.  Sections were stained with hematoxylin and eosin for pathological examination or processed for 
immunohistochemical analysis with antibodies against mouse RPAP1 (for a list of the antibodies used, 
see Table S6, sheet#2).  E3.0 morulae and E4.0 blastocyst embryos were collected in KSOM media 
(Chemicon #3699) and gently resuspended in10% Formalin at 4C overnight to fix.  Next day, embryos 
were resuspended in 100-200 µl of sterile 5% gelatin/dH2O pre-warmed at 37C, then placed at 4C to 
allow gelatin solidification, followed by equilibration of the solid gelatin pellet in cold 10% formalin 
before embedding in paraffin block, and sectioning as above. 
 
Immunofluorescence 
Cells were grown on chamber slides using the same protocols as for the rest of the experiments.  Briefly, 
at day 3 after RPAP1 depletion, cells were fixed with 4% paraformaldehyde for 2 minutes at room 
temperature, washed with PBS and permeabilized with PBS containing 0.02% Tween-20 for 20 minutes. 
Cells were blocked in PBS with 50% Austrailian FBS for 1 h and incubated with antibodies against 
RPAP1 or Pol II (for a list of the antibodies used, see Table S6, sheet#2) at 1:200 to 1:1000 in PBS-
4%BSA, for 3 hrs, washed with PBS and further incubated with secondary anti-rabbit antibodies 
conjugated with Alexa-488, Alex-555 and/or Alexa-647 (1:500 in PBS-4%BSA).  Nuclei were counter-
stained with DAPI. Confocal immunofluorescence cell images were captured using a Leica SP5, 
equipped with white light laser and hybrid detection. 
 
RNA Pol II interactome analysis and LC/LC Mass Spectrometry 
RNA Pol II immunoprecipitation was performed on Day+2 after lentiviral shRNA knockdown of RPAP1 
in primary MEFs.  Cells were washed x2 with ice-cold 1xPBS, then scrape-harvested in ice-cold 1xPBS. 
Lysates were prepared from two replicate experiments, sonicated, and clarified by centrifugation at 10C, 
at 10,000g, for 10 minutes.  The supernatants were pre-cleared by exposure to Protein A/G beads (Santa 
Cruz #sc-2003).  The Pol II complex was immunoprecipitated using a cocktail of three antibodies against 
RPB1/Polr2a, the largest and core catalytic subunit of Pol II, in order to immunoprecipitate Pol II 
throughout all the stages of transcription.  . The antibodies targeted the N-terminus of Pol II (Santa Cruz, 
sc-899x), the Serine5-phosphorylated C-terminal domain (Abcam #5131), and the Serine-2-
phosphorylated C-terminal domain (Abcam #5095).  The immunoprecipitate fraction was eluted, specific 
Pol II protein interactors were determined by Mass Spectrometry, and the Pol II-interactome was 
analysed, as described below. 
 
Immunoprecipitate sample preparation for Mass Spectrometry. 
Proteins were eluted from the agarose beads in two consecutive steps by shaking for 10 min at 1250 rpm 
in an Eppendorf Thermomixer in 2 bead volumes (~100ul) of elution buffer (UT: 8M Urea, 100mM Tris-
HCl pH=8.0).  The supernatant obtained was digested by means of standard FASP (Filter Aided Sample 
Preparation) protocol (Wiśniewski et al., 2009).  Proteins were then reduced with 10 mM DTT, alkylated 
using 50 mM IAA for 20 min in the dark. Proteins were digested with Lys-C (Wako, Neuss, Germany) 
for 6 hours (1:50).  Finally, samples were diluted in 50 mM ammonium bicarbonate to reduce the urea 
concentration to less than 1M, and were subsequently digested with Trypsin (Promega, Madison, WI; 
1:100 sample concentration, overnight at 37 °C).  Resulting peptides were desalted using a Sep-Pak C18 
cartridge for SPE (Waters Corp., Milford, MA).  Eluted peptides were vacuum-dried.  To 
comprehensively identify the Pol II interactome, peptides were further pre-fractionated into five fractions 
using high pH reverse phase micro-columns (Batth et al., 2014), packing three discs (16 g diameter) of 
3M Empore C18 at the bottom of a conventional 200 µL micropipette tip.  After conditioning the tip, 
peptides were dissolved in 50 µl of Buffer A (20mM NH3, pH ≥ 10).  Using an adapter, the tip was 
mounted on a 1.5 mL tube and fit in a benchtop centrifuge.  During each fractionation step, centrifuge 
was operated at 1500 g for 2 min until all the volume passed through the C18 membrane.  Peptides were 
subsequently eluted increasing the percentage of Buffer B (20mM NH3 in CH3CN) (i.e. 4, 8, 12, 80%) of 
Buffer B.  All the five fractions and the flow through were dried in the speed-vac and resuspended in 22 
µl 0.5% FA. 
 
LC−MS/MS Analysis 
	The five fractions of the eight different samples were analyzed by RP chromatography using a nanoLC 
Ultra system (Eksigent, Dublin, CA), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo) 
via nanoESI (Proxeon Biosystems, Waltham, MA).  Peptides were loaded onto a Reprosil-Pur C18 
column (3 µm, 400x0.075 mm; Dr. Maisch, Ammerbuch-Entringen Germany), with a trapping column 
(Prot Trap Column 0.3 x 10 mm, ReproSil C18-AQ, 5 µm), for 10 min with a flow rate of 2.5 L/min of 
loading buffer (0.1% FA).  Elution was performed with a 120 min linear gradient (buffer A: 2% ACN, 
0.1%FA; buffer B: 100% ACN, 0.1%FA) at 300 nL/min.  Peptides were directly electrosprayed into the 
mass spectrometer using a PicoTip emitter (360/20 OD/ID µm tip ID 10 µm, New Objective) at 1.4 kV 
spray voltage with a heated capillary temperature of 325°C and S-Lens of 60%.  Mass spectra were 
acquired in a data-dependent manner, with an automatic switch between MS and MS/MS scans using a 
top 10 method.  MS spectra were acquired with a resolution of 60,000 (FWHM) at 400 m/z in the 
Orbitrap, scanning a mass range between 350 and 1500 m/z (AGC = 1e6, Max IT = 500 ms).  Peptide 
fragmentation was performed using collision-induced dissociation (CID) with read out in the ion trap 
(AGC = 5e3, Max IT = 100 ms) and a normalized collision energy of 35%. 
 
Protein Pol II-interactome Data Collection and Analysis 
Forty raw files (i.e. two experiments “SCR-Pol II vs SCR-IgG” and “shRPAP1-Pol II vs shRPAP1-IgG” 
with two biological replicates each and fractionated into five fractions), were analyzed using MaxQuant 
1.5.3.30 (Cox and Mann, 2008) with Andromeda (Cox et al., 2011) as the search engine against a Mus 
musculus database (UniProtKB/Swiss-Prot, 43,539 sequences).  Carbamidomethylation of cysteine was 
included as fixed modification and oxidation of methionine, acetylation of protein N-terminal were 
included as variable modifications.  Precursor mass tolerance was 20 ppm for the first search, and 4.5 
ppm for the main search.  Fragment mass tolerance was set to 0.5 Da.  Minimal peptide length was set to 
6 amino acids and a maximum of two missed-cleavages were allowed.  Peptides were filtered at 1% FDR.  
For protein assessment (FDR <1%) in MaxQuant, at least one unique peptide was required for both 
identification and quantification.  Other parameters were set as default.  A total of 4,384 proteins were 
identified.  Afterwards, the “protein-group” file was loaded in Perseus (v1.5.1.6) (Tyanova et al., 2016).  
After removing proteins annotated as contaminants, only identified by site and/or reversed a total of 3,944 
proteins were quantified.  Missing values in the IgG runs were replaced by the minimum LFQ value (i.e. 
10) detected in the whole experiment.  Using the LFQ values, all four possible pairwise comparisons 
between the two biological replicates of “SCR-Pol II vs SCR-IgG” were calculated.  The same four 
comparisons were calculated for the “shRPAP1-Pol II vs shRPAP1-IgG” experiments.  A protein was 
declared as specific interactor when the log2 enrichment ratio against its IgG was larger than 2.5 in three 
out of the four comparisons in at least one of the two IP experiments.  In total, 294 proteins were found as 
specific interactors (see Table S4). Among them, we identified all the subunits of the RNA pol II 
complex (12 proteins) and 28 out of 30 subunits of the Mediator complex.  To identify interactors 
affected upon RPAP1 depletion, the data were normalized using the RPB1/Polr2a bait protein levels.  
Then, all four possible pairwise comparisons between “shRPAP-Pol II vs SCR-Pol II” experiments were 
calculated, and proteins were declared to be decreasing in the shRPAP1 if the log2 ratio was smaller than 
-1.5 in three out of the four comparisons.  Proteins were declared to be increasing in the shRPAP-pol II if 
the log2 ratio was larger than 1.5 in three out of the four comparisons.  The RPB1/Polr2a interactome in 
cells treated with the shRPAP1 showed alterations, specifically 104 interactors were absent or 
significantly reduced, while 5 new interactors were found (see Table S4).  The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaino et 
al., 2016) partner repository with the dataset identifier PXD007114. 
 
 
Protein Pol II-interactome Functional analysis 
The interactors found to be affected in the RPAP1-depleted cells were functionally categorized using 
Panther database (http://pantherdb.org) by GO molecular function, GO biological process and GO cellular 
component.  Statistical over-representation of GO terms (mouse genome was used as the background data 
set) was determined with a Binomial test and used the Bonferroni correction for multiple testing.  P-
values were then –log10 transformed for better graphical representation.  These analyses revealed that the 
affected interactors in shRPAP1 were enriched in processes related to transcription and splicing 
(p<0.00001) (Figure S4E). 
To find out whether these affected pol II-interactor proteins belong to specific complexes, we 
mapped our interactome data to the Corum database (Comprehensive resource of mammalian protein 
complexes) (http://mips.helmholtz-muenchen.de/corum/) that contains more than 3000 manually curated 
mammalian protein complexes.  The number of subunits identified in the interactome data (specific 
interactors) for each known complex was retrieved.  The same mapping was done with the list of 
	interactors found to be affected in the RPAP1-depleted cells.  Corum complexes with less than 6 subunits 
were not considered and redundant complexes (those sharing identical subsets of proteins) were also 
removed.  Several well-known complexes were represented in our dataset of Pol II-interactors which 
were affected by RPAP1 depletion (Table S4).  Among them, the Mediator complex (which is formed by 
30 subunits) was ranked the highest (Figure 4E) with eleven subunits affected following RPAP1 
depletion (MED27, MED28, MED9, MED13, MED25, MED22, MED29, MED10, MED31, CDK8, 
MED14) indicating an important alteration in the functions controlled by this complex. 
 
 
RNA isolation and Quantitative real-time PCR (qPCR) 
Total RNA was extracted from cells on column by RNeasy kit with DNA digestion following provider’s 
recommendations (Qiagen # 74104) and retrotranscribed into cDNA following manufacturer´s protocol 
with Superscript Reverse Transcriptase (Life Technologies). Quantitative real time-PCR was performed 
using Syber Green Power PCR Master Mix (Applied Biosystems) in an ABI PRISM 7700 thermocycler 
(Applied Biosystem).  Input normalization of all the qRT-PCR data was by the 2-DDCt method (Yuan et al., 
2006) using the housekeeping genes β-Actin or Gapdh as indicated in each Figure, and as described 
(Ortega-Molina et al., 2015).  Primers used are in Table S6, sheet#1. 
 
RNA-seq transcriptomic analyses 
For RNA-seq, samples of 1 µg of total RNA, with RIN numbers in the range 9.8 to 10 (Agilent 2100 
Bioanalyzer), was used. PolyA+ fractions were processed using TruSeq Stranded mRNA Sample 
Preparation Kit (Agilent).  Adapter-ligated library was completed by PCR with Illumina PE primers (8 
cycles).  The resulting directional cDNA libraries were sequenced for 40 bases in a single-read format 
(Genome Analyzer IIx, Illumina).  The complete set of reads has been deposited in GEO (GSE78795).  
Sequencing quality for RNA-seq samples was analyzed with FastQC. Reads were aligned to the mouse 
genome (GRCm38/mm10) with TopHat-2.0.4 (Trapnell et al., 2012) (using Bowtie 0.12.7 (Langmead et 
al., 2009) and Samtools 0.1.16 (Li et al., 2009c), allowing two mismatches and five multihits.  Transcripts 
assembly, estimation of their abundance, and differential expression, were calculated with Cufflinks 1.3.0 
(Trapnell et al., 2012), using the mouse genome annotation data set GRCm38/mm10 from the UCSC 
Genome Browser (Rosenbloom et al., 2015).   
 
Functional analyses of differential gene expression 
For differential gene expression lists (see data in Table S1: ES cells +24hr differentiation; or Table S3: 
MEFs at day 3 after RPAP1 depletion).  Genes were ranked using the FDR q-value statistic to identify 
significant genes (FDR<0.05 or FDR<0.01, as indicated in the Figures), then by fold change in 
expression.  Selected differentially-expressed genes identified in the RNA-seq were validated by qPCR.  
Venn diagrams were generated by JVenn (Bardou et al., 2014) and hypergeometric testing was performed 
to assess any significant overlaps.  Pathway analyses were by Ingenuity Pathway Analysis software 
(www.ingenuity.com).  Gene Set Enrichment Analysis (GSEA; Subramanian et al., 2005).  GSEAPre-
ranked was used to perform a gene set enrichment analysis of annotations from the MsigDB Hallmarks, 
C5-Gene Ontoly (GO) terms, C2-Curated, KEGG, Reactome and NCI databases, with standard GSEA 
and Leading Edge analysis settings.  We used the RNA-seq gene list ranked by statistic, setting ‘gene set’ 
as the permutation method and ran it with 1000 permutations for Kolmogorov-Smirnoff correction for 
multiple testing. We considered only those gene sets with significant enrichment levels (FDR q-value <  
0.25) ( Subramanian et al., 2005) (see: Table S2).  GSEA Enrichment data were obtained and ranked 
according to their FDR q-value (see: Table S2).  Heatmaps of GSEA data (Figures 2H and 5F) or qPCR 
data (Figure 3G) were generated using Gene Pattern (Reich et al., 2006). 
 
Supervised Network Analysis 
Investigation of differential gene expression for dominant gene-ontologies or functions was performed by 
supervised network analyses.  Briefly, network analyses were performed starting from the list of 
differentially expressed genes induced by RPAP1 depletion followed by 24hrs of ES differentiation, or 
separately, RPAP1 depletion for 3 days in MEFs. Next these lists were used to find gene interaction 
information in the Metacore™ database, including manually curated experimentally validated interaction 
data.  The interaction datasets generated (including information of the interaction direction –i.e. source 
and target genes– and interaction effect –i.e. inhibition or activation–) were contextualized for obtaining 
the gene regulatory networks of the RPAP1-depletion and control phenotypes, using an algorithm 
developed in-house (Crespo et al., 2013; Zickenrott S et al., 2016).  Finally, the phenotype-specific 
networks were compared to identify the pathway enrichment in genes in the “up-regulated” or “down-
regulated” lists. In this comparison we estimate the statistical significance (i.e. enrichment) of the 
	interactions among genes in each category, which constitute an indication of the differences in the 
regulatory mechanisms underlying the phenotypical changes caused by RPAP1 depletion.  See Table S1, 
sheets#6-11; and Table S3, sheets#6-10. 
 
Comparison of differential gene expression with the iPS roadmap 
Gene expression changes have been comprehensively characterized in the subset of successfully-
progressing cells during iPS reprogramming by overexpression of the OSKM Yamanaka factors (Polo et 
al., 2012; Hansson et al., 2012).  We first identified the gene expression changes which occur between 
day 0 and day +3, or between day 0 and day +9, of successful iPS reprogramming by comparing RNA-
seq data in the parental MEFs (day 0) versus day +3 (or day +9) Thy1-negative cells in the published 
datasets. Next, we used GSEA to compare these iPS roadmap genesets of top 100 or top 500 up- or down-
regulated mRNAs versus the complete ranked list of differential gene expression in MEFs at day 3 after 
RPAP1 depletion.  We also performed the analysis in reverse, comparing the genesets of significantly 
differentially expressed mRNAs up- or down-regulated in MEFs at day 3 after RPAP1 depletion, versus, 
the complete ranked list of differential gene expression at day 3 (or day 9) of the iPS roadmap.  GSEA 
results are shown in Figure 3A and S3A and S3B.  Data with P<0.05 and FDR<0.25 are considered 
significant. 
 
Conversion of Plant gene expression data to Mammalian homologs 
The effect of RPAP1-mutation on mRNA expression levels was previously published in Arabidopsis 
(Sanmartin et al., 2011).  We converted the published data from plant (31,200 genes; see: Table S2, 
sheet#4) to mammal (mouse) via protein sequence similarity (Table S2, sheets #5 and #6), filtering the 
data by three thresholds: (i) “100% coverage”, that is, the whole plant protein is included in the alignment 
against whole mouse proteins; (ii) the best “%amino acid Identity” possible, always greater than 20% (% 
of amino acids than are totally conserved in both sequences); (iii) the best “%Positive amino acids” as 
possible (this takes into account synonymous amino acids (that is based on similarity in terms of size and 
charge).  We filtered out: 250 genes that did not map (neither in Arabidopsis TAIR 10 database nor in 
EnsEMBL), and a further 1933 Arabidopsis genes were without homology/orthology in mouse, however, 
the majority of these were transposons (Table S2, sheet#7).  We ran GSEA using the MSigDB Hallmark, 
C5-GO terms, and C2-Curated databases against the entire remaining ranked list of homolous plant 
proteins/genes (for the ranked list of genes converted to mouse, see Table S2, sheets #5 and #6) to 
identify significant genesets up or down-regulated by RPAP1-mutation in plants which have a homolog 
in mouse (see summary of results in Table S2, sheet #7).  In Figure 5F, the heatmap compares the 
GSEA hallmark database analysis from the plant-mammal conversion above (Table S2, sheet #7), 
versus, the GSEA hallmark database analyses results for three other experiments: (i) GSEA on the ranked 
list of differential mRNA expression in MEFs at day 3 +/- RPAP1-depletion; (ii) GSEA on the ranked list 
of differential mRNA expression in ES cells at +24hrs after inducing differentiation, +/- RPAP1-
depetion; (iii) GSEA on the ranked list of differential RNA Pol II abundance at the promoter at day 3 +/- 
RPAP1 depletion. 
 
Chromatin Immunoprecipitation (ChIP) and deep-sequencing 
ChIP-qPCR was performed as described (Li et al., 2012) with primers listed in Table S6 and antibodies 
for Total Pol II (Santa Cruz N20, sc-899x) and RPAP1 (Cosmo Bio MK14030910).  ChIP-seq for Pol II 
was performed as described (Rahl et al., 2010).  Briefly, cells were fixed using 1% formaldehyde, scrape-
harvested, resuspended in ChIP lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl, pH 8.1) and 
sonicated using Covaris water bath sonicator to generate fragments of 150 to 500 bp. Soluble chromatin 
was diluted 10 fold in ChIP Dilution buffer (1% Triton X-100, 2 mM EDTA pH 8.0, 150 mM NaCl) 
precleared with Agarose Protein A/G beads (Santa Cruz), and then incuated with antibody specific for 
total RNA Pol II (N-20, sc-899x, Santa Cruz) or specific for the RNA Pol II Ser5P-phoshorylated form 
(Abcam #ab5131).  After incubation, immunocomplexes were collected with Agarose Protein A/G beads 
(Santa Cruz). Next, the immunocomplexes were washed sequentially with Low Salt Wash Buffer (0.1% 
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 150mM NaCl), High Salt Wash Buffer 
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM NaCl), LiCl Wash Buffer 
(0.25M LiCl, 1% NP40, 1% deoxycholate-Na, 1mM EDTA, 10mM Tris-HCl, pH 8.1) and washed twice 
with TE (10 mM Tris-HCl pH7.5, 1mM EDTA). Immunocomplexes were eluted in ChIP elution buffer 
(1%SDS, 0.1M NaHCO3) and the crosslinking was reverted by incubation at 65 ºC for 8 hrs with 200 
mM NaCl. Samples were treated with Proteinase K and RNase A ,and DNA was extracted using Phenol-
Chloroform.  DNA precipitation was in 100% ethanol with 0.1 M NaAcetate ph5.2 and 2 uLs glycogen 
(Roche).  The DNA pellet was washed with 70% ethanol, and resuspended in ddH2O. Purified chromatin 
was used for library construction. 
	For ChIP-seq the amount of DNA used was ~5 ng from each sample (as quantitated by fluorometry). 
Samples were were processed through subsequent enzymatic treatments of end-repair, dA-tailing, and 
ligation to adapters as in Illumina's "TruSeq DNA Sample Preparation Guide" (part # 15005180 Rev. C). 
Adapter-ligated libraries were completed by limited-cycle PCR with Q5 High-Fidelity DNA Polymerase 
(NEB) and Illumina PE primers (15 cycles), and further purified with a double-sided SPRI size selection 
to obtain a size distribution in the range of 230-500bp. Libraries were applied to an Illumina flow cell for 
cluster generation (TruSeq cluster generation kit v5) and sequenced on the Genome Analyzer IIx with 
SBS TruSeq v5 reagents by following manufacturer's protocols, to 20-25 million reads per sample.   
 
Pol II ChIP-seq data analyses 
Definition of promoter and gene body regions (See: Figure S5B) and the calculation of Pol II total and 
Ser5P abundance along genes was based on methods of Young and colleagues (Rahl el al., 2010) (see 
Table S5).  Sequencing quality for ChIP-seq samples was analyzed with FastQC (Andrews, 2011).  
Reads were aligned with Bwa 0.7.5a (Li and Durbin, 2009) to the mouse reference genome 
(GRCm38/mm10) using the default seed length (32) and allowing 1 mismatch in the seed.  SAMtools 
0.1.16 (et al., 2009b) was used to convert the output alignment SAM files to the BAM file format, sort the 
alignments and eliminate duplicated reads.  BEDTools 2.23.0 (Quinlan, 2014) was used to convert the 
resulting files to the BED format.  All ChIP and input samples were randomly normalized to the same 
number of reads.  Peak calling was performed with MACS 2.0.10.20130712 (Feng et al., 2012) using the 
input sample as control for each one of the ChIP samples.  BigWig files were obtained with 
bedGraphToBigWig (Kent et al., 2010) from the BedGraph files generated with MACS.  Resulting peaks 
were annotated with PeakAnalyzer 1.4 (Salmon-Divon et al., 2010), and the distribution of peaks was 
plotted with SeqMiner 1.3.3e (Ye et al., 2014) with color-scaled intensities are in units of reads per 
million mapped reads (rpm).  Transcription Start Sites (TSS) and Transcription Termination Sites (TTS) 
were identified using the Database of Transcriptional Start Sites (http://dbtss.hgc.jp).  Metagenes were 
aligned +/- 5 Kb around the TSS.  The Pausing Index (PI) for gene promoters versus gene bodies was 
calculated as described (Rahl et al., 2010; see also Figure S5B).  First, the number of reads per nucleotide 
was computed with BEDTools 'genomecov'; second, to extend this number to the number of reads per 
gene promoter or gene body, BEDTools 'map' was used; and third, the Pausing Index was calculated for 
each gene promoter or gene body as PI = ((number of reads in region / region size)*scaling factor)*105.   
Scaling factor = (total number of reads in sample/genome length). 
 
Definition of MEF super-enhancers, their target genes, and their eRNA levels 
For Figure 5G: MEF super-enhancers were defined by H3K27Ac ChIP-seq signal and ranking by ROSE, 
as previously described (Whyte et al., 2013; Shen et al., 2012; Khan and Zhang, 2016; dbSUPER, 
http://bioinfo.au.tsinghua.edu.cn/dbsuper/).  To identify the single-nearest target gene to each MEF super-
enhancer, GREAT analysis was performed as described (GREAT v3.0.0; McLean et al., 2010).  In 
Figure 5G, this geneset of MEF super-enhancer target genes was used in GSEA analysis of the mRNA 
expression levels of these genes at day 3 after RPAP1 knockdown in primary MEFs in our data.   
For Figure 5H: the same MEF super-enhancer regions were assessed for enhancer-RNA (eRNA) 
abundance which has been reported to be proportional to enhancer activity (Andersson et al., 2014).  
MEF super-enhancers grouped by K-means clustering according to changes in their eRNA levels at day 3 
after RPAP1 knockdown into 3 groups: increased (~10%, n=64), decreased (~10%, n=63), no-
change/not-detected (~80%).  In Figure 5H, average RNA abundance on the super-enhancers with 
increased or decreased eRNA levels was visualized in 50bp bins from start to end of feature using 
SeqMINER (Ye et al., 2014). 
For Figure S5G, GSEA was performed as described above for Figure 5G, except here, in order 
to assess any changes in housekeeper mRNA expression levels.  No significant change in housekeeper 
gene expression was detected, despite performing GSEA using the following housekeeper genesets: (i) a 
full set of 3,384 housekeeper genes (defined in Eisenberg and Levanon, 2013); (ii) 10 sets of 500 genes, 
each randomly selected from the full 3,384 housekeepers, performed so that the individual genes could be 
visualized in the GSEA enrichment plot.  The data shown in Figure S5G is representative of one of the 
random selections of 500 housekeeper genes from the above list of 3,384 genes where no significant 
change in housekeeper mRNA was detected. 
For Figures S5H, S5I, and S5J: GREAT analysis (GREAT v3.0.0; McLean et al., 2010) was 
performed on the following two groups of super-enhancers, defined above, to identify the single-nearest 
target gene of each super-enhancer: (i) super-enhancers with increased eRNA levels (Figure S5H); (ii) 
super-enhancers with decreased eRNA levels (Figures S5I and S5J).  Next, these two enhancer-target-
gene groups were assessed separately for any enrichments in their functions (Gene Ontology Biological 
process) or the developmental stage associated with their expression (MGI Expression-Detected; Theiler 
	Stage of embryo development).  The data is presented in Figures S5H to S5J.  In Figure 5I, the Theiler 
Stage of embryo development associated with these two enhancer-target-gene groups (the enhancers with 
increased or decreased eRNA/activity levels) is shown, together with the approximate embryo day-post-
coitus (dpc) (emouseatlas.org; Bard et al., 1998).  Super-enhancers with decreased eRNA levels (and thus 
putatively decreased activity) were associated with target-genes expressed during the period embryo dpc 
E11.5-E17.  Conversely, super-enhancers with increased eRNA levels (and thus putatively increased 
activity) were associated with target-genes expressed during the period embryo dpc E8-E13.  Since 
primary MEFs derive from E13.5, the decrease in activity of enhancers associated with E11.5-E17, 
coupled with the increase in activity of enhancers associated with E8-E13 mirrors the gene expression 
analysis in Figure 2, where MEFs at Day3 after RPAP1 knockdown appear to have de-differentiated, and 
in Figure 3, where this pattern of de-differentiation correlates significantly with the first 3 days of iPS 
reprogramming when MEF cell identity is erased (Polo et al., 2012).	
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Unless otherwise specified quantitative data are presented as mean +/- SD and significance was assessed 
by the two-tailed Student’s t test ; *p<0.05, **p<0.01, ***p<0.001. 
 
 
DATA AND SOFTWARE AVAILABILITY 
Data Resources. Accession Numbers: Three datasets (two RNA-seq and one ChIP-seq experiment) are 
available from the GEO database: GSE78795. The mass spectrometry proteomics data are available from 
the ProteomeXchange Consortium/PRIDE repository with the dataset identifier PXD007114. 
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